Search Results For:
- Search results for:
- covid 19
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage
European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Termination & withdrawal
European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Donation
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Product supply
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Representations & Warranties
CEPI - Dynavax, COVID-19 Material Reservation Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
2020
Industry
Vaccine
Discovery/Concept
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
2021
Government
Multilateral organization
Multilateral organization
Diagnostic
Commercialization
- Equitable Access | Affordable pricing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
2021
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
2021
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Donation
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
2021
Funder
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
2021
Industry
Multilateral organization
Multilateral organization
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Israel - Pfizer, Epidemiological Evidence Collaboration Agreement
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Field Testing
Commercialization
Field Testing
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | Ownership of IP
- Liability | Representations & Warranties
BARDA - Moderna, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Early clinical (through Phase 2)
Late clinical (Phase 3)
- Equitable Access | Ensuring continuity
- Business model | Governance
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
2020
Industry
Drug
Vaccine
Vaccine
Preclinical
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
MSD - MPP, Molnupiravir License Agreement
2021
Industry
Multilateral organization
Multilateral organization
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
NIH - GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
2020
Government
Industry
Industry
Vaccine
Preclinical
Commercialization
Commercialization
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
NIH - MPP, COVID-19 Patent and Biological Material License Agreement
2022
Government
Multilateral organization
Multilateral organization
Diagnostic
Drug
Vaccine
Drug
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Late clinical (Phase 3)
Commercialization
- Equitable Access | Access plans & principles
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
CEPI - Novavax, COVID-19 Vaccine Funding Agreement
2020
Funder
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Access plans & principles
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Equitable Access | Territory access commitments
- Business model | Benefit sharing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
2020
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Territory access commitments
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
2021
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Protecting & sharing information | Technology transfer
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Insurance
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Intellectual Property | Ownership of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Liability | Representations & Warranties
- Term & termination | Term of agreement
Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
2021
Government
Industry
Industry
Vaccine
Late clinical (Phase 3)
Commercialization
Commercialization
US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
2020
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Business model | Regulatory strategy
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Information sharing
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
2020
Government
Industry
Industry
Vaccine
Early clinical (through Phase 2)
Late clinical (Phase 3)
Commercialization
Field Testing
Late clinical (Phase 3)
Commercialization
Field Testing
- Equitable Access | Ensuring continuity
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Liability | Indemnification & liability
US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
2020
Government
Industry
Industry
Vaccine
Commercialization
- Equitable Access | Ensuring continuity
- Equitable Access | Preparedness & response
- Equitable Access | Affordable pricing
- Business model | Regulatory strategy
- Business model | Governance
- Business model | Payment Structures
- Business model | Product supply
- Protecting & sharing information | Confidentiality
- Protecting & sharing information | Information sharing
- Protecting & sharing information | Publication of Results
- Intellectual Property | License Grants
- Intellectual Property | Ownership of IP
- Intellectual Property | Protection of IP
- Liability | Indemnification & liability
- Liability | Representations & Warranties
- Term & termination | Effects of termination
- Term & termination | Term of agreement
- Term & termination | Termination & withdrawal
UK Secretary of State - Roche, REGN-COV2 Supply Agreement
2021
Government
Industry
Industry
Drug
Late clinical (Phase 3)
Commercialization
Commercialization
GHIAA2019\MapguideSearch Object
(
[search_parameters] => Array
(
[qs] => covid 19
)
[filters] => Array
(
[text_search] => covid 19
)
[child_filters] => Array
(
)
[agreement_args] =>
[provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[post__in] => Array
(
[0] => 5782
[1] => 5653
[2] => 5652
[3] => 5620
[4] => 5619
[5] => 5618
[6] => 5617
[7] => 5616
[8] => 5615
[9] => 5614
[10] => 5612
[11] => 5611
[12] => 5610
[13] => 5609
[14] => 5608
[15] => 5599
[16] => 5596
[17] => 5595
[18] => 5594
[19] => 5593
[20] => 5592
[21] => 5591
[22] => 5429
[23] => 5123
[24] => 5122
[25] => 5121
[26] => 5120
[27] => 5119
[28] => 5118
[29] => 5117
[30] => 5116
[31] => 5115
[32] => 5114
[33] => 5113
[34] => 5112
[35] => 5111
[36] => 4808
[37] => 4807
[38] => 4806
[39] => 4805
[40] => 4804
[41] => 4802
[42] => 4801
[43] => 4800
[44] => 4798
[45] => 4797
[46] => 4796
[47] => 4661
[48] => 4147
[49] => 4601
[50] => 4148
[51] => 4223
[52] => 4222
[53] => 4221
[54] => 4220
[55] => 4219
[56] => 4218
[57] => 4217
[58] => 4216
[59] => 4215
[60] => 4214
[61] => 4213
[62] => 4212
[63] => 4210
[64] => 4209
[65] => 4205
[66] => 4204
[67] => 4201
[68] => 4200
[69] => 4161
[70] => 4159
[71] => 4158
[72] => 4157
[73] => 4156
[74] => 4155
[75] => 4154
[76] => 4153
[77] => 4152
[78] => 4151
[79] => 4150
[80] => 4149
[81] => 4146
[82] => 4141
[83] => 4140
[84] => 4139
[85] => 4138
[86] => 4137
[87] => 4136
[88] => 4135
[89] => 4134
[90] => 4133
[91] => 4131
[92] => 4130
[93] => 4129
[94] => 4128
[95] => 4058
[96] => 4054
[97] => 4051
[98] => 4050
[99] => 4047
[100] => 4046
[101] => 4045
[102] => 4043
[103] => 4042
[104] => 4041
[105] => 4040
[106] => 4038
[107] => 4036
[108] => 4035
[109] => 4032
[110] => 4029
[111] => 4028
[112] => 4024
[113] => 4022
[114] => 4021
[115] => 4020
[116] => 4017
[117] => 4016
[118] => 4014
[119] => 4013
[120] => 4011
[121] => 4009
[122] => 4007
[123] => 4006
[124] => 4004
[125] => 4003
[126] => 4002
[127] => 3997
[128] => 3869
[129] => 3886
[130] => 3884
[131] => 3883
[132] => 3882
[133] => 3881
[134] => 3880
[135] => 3878
[136] => 3877
[137] => 3876
[138] => 3875
[139] => 3874
[140] => 3873
[141] => 3870
[142] => 3863
[143] => 3861
[144] => 3860
[145] => 3859
[146] => 3858
[147] => 3857
[148] => 3856
[149] => 3855
[150] => 3854
[151] => 3852
[152] => 3851
[153] => 3849
[154] => 3848
[155] => 3847
[156] => 3846
[157] => 3819
[158] => 3812
[159] => 3810
[160] => 3809
[161] => 3808
[162] => 3807
[163] => 3806
[164] => 3805
[165] => 3804
[166] => 3803
[167] => 3802
[168] => 3801
[169] => 3800
[170] => 3799
[171] => 3798
[172] => 3797
[173] => 3796
[174] => 3792
[175] => 3791
[176] => 3789
[177] => 3788
[178] => 3786
[179] => 3785
[180] => 3784
[181] => 3783
[182] => 3782
[183] => 3781
[184] => 3778
[185] => 3765
[186] => 3764
[187] => 3758
[188] => 3741
[189] => 3696
[190] => 3495
[191] => 3493
[192] => 3436
[193] => 3434
[194] => 3433
[195] => 3431
[196] => 3430
[197] => 3428
[198] => 3427
[199] => 3426
[200] => 3424
[201] => 3422
[202] => 3421
[203] => 3420
[204] => 3372
[205] => 3370
[206] => 3368
[207] => 3366
[208] => 3364
[209] => 3361
[210] => 3360
[211] => 3356
[212] => 3354
[213] => 3352
[214] => 3221
[215] => 3220
[216] => 3219
[217] => 3218
[218] => 3217
[219] => 3216
[220] => 3215
[221] => 3127
[222] => 3126
[223] => 3125
[224] => 3124
[225] => 3123
[226] => 3122
[227] => 3121
[228] => 3120
[229] => 3119
[230] => 2956
[231] => 2961
[232] => 2965
[233] => 2947
[234] => 2960
[235] => 2964
[236] => 2958
[237] => 2949
[238] => 2957
[239] => 2962
[240] => 2945
[241] => 2909
[242] => 2908
[243] => 2907
[244] => 2893
[245] => 2892
[246] => 2890
[247] => 2889
[248] => 2885
[249] => 2824
[250] => 2823
[251] => 2822
[252] => 2820
[253] => 2744
[254] => 2749
[255] => 2748
[256] => 2743
[257] => 2742
[258] => 2741
[259] => 2739
[260] => 2737
[261] => 2736
[262] => 2734
[263] => 2543
[264] => 2540
[265] => 2541
[266] => 2542
[267] => 2544
[268] => 2545
[269] => 2547
[270] => 2549
[271] => 2553
[272] => 2457
[273] => 2461
[274] => 2462
[275] => 2463
[276] => 2464
[277] => 2465
[278] => 2466
[279] => 2467
[280] => 2470
[281] => 2473
[282] => 2474
[283] => 2475
[284] => 2476
[285] => 2477
[286] => 2479
[287] => 2481
[288] => 2482
[289] => 2471
[290] => 2452
[291] => 2450
[292] => 2449
[293] => 2448
[294] => 2444
[295] => 2443
[296] => 2442
[297] => 2441
[298] => 2426
[299] => 2424
[300] => 5782
[301] => 5653
[302] => 5652
[303] => 5620
[304] => 5619
[305] => 5618
[306] => 5617
[307] => 5616
[308] => 5615
[309] => 5614
[310] => 5612
[311] => 5611
[312] => 5610
[313] => 5609
[314] => 5608
[315] => 5599
[316] => 5596
[317] => 5595
[318] => 5594
[319] => 5593
[320] => 5592
[321] => 5591
[322] => 5429
[323] => 5123
[324] => 5122
[325] => 5121
[326] => 5120
[327] => 5119
[328] => 5118
[329] => 5117
[330] => 5116
[331] => 5115
[332] => 5114
[333] => 5113
[334] => 5112
[335] => 5111
[336] => 4808
[337] => 4807
[338] => 4806
[339] => 4805
[340] => 4804
[341] => 4802
[342] => 4801
[343] => 4800
[344] => 4798
[345] => 4797
[346] => 4796
[347] => 4661
[348] => 4147
[349] => 4601
[350] => 4148
[351] => 4223
[352] => 4222
[353] => 4221
[354] => 4220
[355] => 4219
[356] => 4218
[357] => 4217
[358] => 4216
[359] => 4215
[360] => 4214
[361] => 4213
[362] => 4212
[363] => 4210
[364] => 4209
[365] => 4205
[366] => 4204
[367] => 4201
[368] => 4200
[369] => 4161
[370] => 4159
[371] => 4158
[372] => 4157
[373] => 4156
[374] => 4155
[375] => 4154
[376] => 4153
[377] => 4152
[378] => 4151
[379] => 4150
[380] => 4149
[381] => 4146
[382] => 4141
[383] => 4140
[384] => 4139
[385] => 4138
[386] => 4137
[387] => 4136
[388] => 4135
[389] => 4134
[390] => 4133
[391] => 4131
[392] => 4130
[393] => 4129
[394] => 4128
[395] => 4058
[396] => 4054
[397] => 4051
[398] => 4050
[399] => 4047
[400] => 4046
[401] => 4045
[402] => 4043
[403] => 4042
[404] => 4041
[405] => 4040
[406] => 4038
[407] => 4036
[408] => 4035
[409] => 4032
[410] => 4029
[411] => 4028
[412] => 4024
[413] => 4022
[414] => 4021
[415] => 4020
[416] => 4017
[417] => 4016
[418] => 4014
[419] => 4013
[420] => 4011
[421] => 4009
[422] => 4007
[423] => 4006
[424] => 4004
[425] => 4003
[426] => 4002
[427] => 3997
[428] => 3869
[429] => 3886
[430] => 3884
[431] => 3883
[432] => 3882
[433] => 3881
[434] => 3880
[435] => 3878
[436] => 3877
[437] => 3876
[438] => 3875
[439] => 3874
[440] => 3873
[441] => 3870
[442] => 3863
[443] => 3861
[444] => 3860
[445] => 3859
[446] => 3858
[447] => 3857
[448] => 3856
[449] => 3855
[450] => 3854
[451] => 3852
[452] => 3851
[453] => 3849
[454] => 3848
[455] => 3847
[456] => 3846
[457] => 3819
[458] => 3812
[459] => 3810
[460] => 3809
[461] => 3808
[462] => 3807
[463] => 3806
[464] => 3805
[465] => 3804
[466] => 3803
[467] => 3802
[468] => 3801
[469] => 3800
[470] => 3799
[471] => 3798
[472] => 3797
[473] => 3796
[474] => 3792
[475] => 3791
[476] => 3789
[477] => 3788
[478] => 3786
[479] => 3785
[480] => 3784
[481] => 3783
[482] => 3782
[483] => 3781
[484] => 3778
[485] => 3765
[486] => 3764
[487] => 3758
[488] => 3741
[489] => 3696
[490] => 3495
[491] => 3493
[492] => 3436
[493] => 3434
[494] => 3433
[495] => 3431
[496] => 3430
[497] => 3428
[498] => 3427
[499] => 3426
[500] => 3424
[501] => 3422
[502] => 3421
[503] => 3420
[504] => 3372
[505] => 3370
[506] => 3368
[507] => 3366
[508] => 3364
[509] => 3361
[510] => 3360
[511] => 3356
[512] => 3354
[513] => 3352
[514] => 3221
[515] => 3220
[516] => 3219
[517] => 3218
[518] => 3217
[519] => 3216
[520] => 3215
[521] => 3127
[522] => 3126
[523] => 3125
[524] => 3124
[525] => 3123
[526] => 3122
[527] => 3121
[528] => 3120
[529] => 3119
[530] => 2956
[531] => 2961
[532] => 2965
[533] => 2947
[534] => 2960
[535] => 2964
[536] => 2958
[537] => 2949
[538] => 2957
[539] => 2962
[540] => 2945
[541] => 2909
[542] => 2908
[543] => 2907
[544] => 2893
[545] => 2892
[546] => 2890
[547] => 2889
[548] => 2885
[549] => 2824
[550] => 2823
[551] => 2822
[552] => 2820
[553] => 2744
[554] => 2749
[555] => 2748
[556] => 2743
[557] => 2742
[558] => 2741
[559] => 2739
[560] => 2737
[561] => 2736
[562] => 2734
[563] => 2543
[564] => 2540
[565] => 2541
[566] => 2542
[567] => 2544
[568] => 2545
[569] => 2547
[570] => 2549
[571] => 2553
[572] => 2457
[573] => 2461
[574] => 2462
[575] => 2463
[576] => 2464
[577] => 2465
[578] => 2466
[579] => 2467
[580] => 2470
[581] => 2473
[582] => 2474
[583] => 2475
[584] => 2476
[585] => 2477
[586] => 2479
[587] => 2481
[588] => 2482
[589] => 2471
[590] => 2452
[591] => 2450
[592] => 2449
[593] => 2448
[594] => 2444
[595] => 2443
[596] => 2442
[597] => 2441
[598] => 2426
[599] => 2424
[600] => 3909
[601] => 3908
[602] => 3906
[603] => 3904
[604] => 3903
[605] => 3901
[606] => 3900
[607] => 3899
[608] => 3898
[609] => 3897
[610] => 3896
[611] => 3895
[612] => 3892
[613] => 3891
[614] => 3418
[615] => 3417
[616] => 3416
[617] => 3415
[618] => 3414
[619] => 3413
[620] => 3412
[621] => 3411
[622] => 3410
[623] => 3409
[624] => 3406
[625] => 3304
[626] => 2873
[627] => 2872
[628] => 2870
[629] => 2869
[630] => 2867
)
)
[text_agreement_args] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
)
[text_provision_args] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
)
[agreement_ids] => Array
(
)
[agreement_q_rslts] =>
[provision_q_rslts] =>
[text_agreement_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
)
[query_vars] => Array
(
[post_type] => agreement
[posts_per_page] => -1
[s] => covid 19
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[orderby] => title
[order] => ASC
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 2
[search_terms] => Array
(
[0] => covid
[1] => 19
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}covid{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}'
[1] => wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}19{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}'
)
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT DISTINCT wpry_posts.*
FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) )
WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) ) AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
ORDER BY wpry_posts.post_title ASC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 2438
[post_author] => 5
[post_date] => 2021-01-19 06:43:39
[post_date_gmt] => 2021-01-19 06:43:39
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:05:25
[post_modified_gmt] => 2021-09-15 12:05:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2438
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 4207
[post_author] => 5
[post_date] => 2022-03-02 11:38:41
[post_date_gmt] => 2022-03-02 11:38:41
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-02 11:38:51
[post_modified_gmt] => 2022-03-02 11:38:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4207
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 4126
[post_author] => 5
[post_date] => 2022-01-28 13:33:11
[post_date_gmt] => 2022-01-28 13:33:11
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:33:11
[post_modified_gmt] => 2022-01-28 13:33:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4126
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 2882
[post_author] => 6
[post_date] => 2021-05-14 14:03:29
[post_date_gmt] => 2021-05-14 14:03:29
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 11:58:31
[post_modified_gmt] => 2021-09-15 11:58:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2882
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 4794
[post_author] => 5
[post_date] => 2022-05-23 13:54:39
[post_date_gmt] => 2022-05-23 13:54:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 13:54:39
[post_modified_gmt] => 2022-05-23 13:54:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4794
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 3817
[post_author] => 6
[post_date] => 2021-09-15 10:46:18
[post_date_gmt] => 2021-09-15 10:46:18
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 13:58:20
[post_modified_gmt] => 2021-12-13 13:58:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3817
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 3117
[post_author] => 6
[post_date] => 2021-06-03 14:15:12
[post_date_gmt] => 2021-06-03 14:15:12
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:00:38
[post_modified_gmt] => 2021-09-15 12:00:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3117
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 2538
[post_author] => 5
[post_date] => 2021-03-12 13:41:11
[post_date_gmt] => 2021-03-12 13:41:11
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => advance-purchase-agreement-for-the-production-purchase-and-supply-of-a-covid-19-vaccine-in-the-european-union-with-astrazeneca
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:05:41
[post_modified_gmt] => 2021-09-15 12:05:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2538
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 2468
[post_author] => 5
[post_date] => 2021-02-25 15:15:43
[post_date_gmt] => 2021-02-25 15:15:43
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => advance-purchase-agreement-for-the-development-production-advance-purchase-and-supply-of-a-covid-19-vaccine-for-eu-member-states-with-curevac
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:00:56
[post_modified_gmt] => 2021-09-15 12:00:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2468
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 3419
[post_author] => 6
[post_date] => 2021-07-01 01:45:34
[post_date_gmt] => 2021-07-01 01:45:34
[post_content] =>
[post_title] => Fiocruz - AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-10 18:22:02
[post_modified_gmt] => 2021-11-10 18:22:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3419
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 3843
[post_author] => 5
[post_date] => 2021-11-05 10:54:08
[post_date_gmt] => 2021-11-05 10:54:08
[post_content] =>
[post_title] => Fiocruz - AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-05 10:54:08
[post_modified_gmt] => 2021-11-05 10:54:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3843
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 5586
[post_author] => 5
[post_date] => 2022-08-11 09:34:02
[post_date_gmt] => 2022-08-11 09:34:02
[post_content] =>
[post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => bmgf-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 09:37:27
[post_modified_gmt] => 2022-08-11 09:37:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=5586
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 5589
[post_author] => 5
[post_date] => 2022-08-11 09:35:21
[post_date_gmt] => 2022-08-11 09:35:21
[post_content] =>
[post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 09:35:21
[post_modified_gmt] => 2022-08-11 09:35:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=5589
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 4142
[post_author] => 5
[post_date] => 2022-02-01 18:56:28
[post_date_gmt] => 2022-02-01 18:56:28
[post_content] =>
[post_title] => Gavi Alliance - Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 07:30:00
[post_modified_gmt] => 2022-02-02 07:30:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4142
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 3867
[post_author] => 5
[post_date] => 2021-11-18 12:26:40
[post_date_gmt] => 2021-11-18 12:26:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 12:26:40
[post_modified_gmt] => 2021-11-18 12:26:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3867
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 3348
[post_author] => 5
[post_date] => 2021-06-30 13:13:40
[post_date_gmt] => 2021-06-30 13:13:40
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:18:24
[post_modified_gmt] => 2021-09-15 12:18:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3348
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 5110
[post_author] => 5
[post_date] => 2022-06-29 11:57:22
[post_date_gmt] => 2022-06-29 11:57:22
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 11:57:22
[post_modified_gmt] => 2022-06-29 11:57:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=5110
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 3794
[post_author] => 5
[post_date] => 2021-09-10 08:02:49
[post_date_gmt] => 2021-09-10 08:02:49
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:20:53
[post_modified_gmt] => 2021-09-15 12:20:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3794
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 4026
[post_author] => 5
[post_date] => 2021-12-21 11:36:17
[post_date_gmt] => 2021-12-21 11:36:17
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-21 11:36:17
[post_modified_gmt] => 2021-12-21 11:36:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=4026
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 3213
[post_author] => 6
[post_date] => 2021-06-28 12:04:36
[post_date_gmt] => 2021-06-28 12:04:36
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:03:12
[post_modified_gmt] => 2021-09-15 12:03:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3213
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 2420
[post_author] => 5
[post_date] => 2020-12-14 14:59:07
[post_date_gmt] => 2020-12-14 14:59:07
[post_content] =>
[post_title] => Sanofi - Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => collaboration-and-license-agreement-between-sanofi-pasteur-inc-sanofi-and-translate-bio-ma-inc-translate-bio-or-tb-and-first-amendment-co
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:03:29
[post_modified_gmt] => 2021-09-15 12:03:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2420
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 2943
[post_author] => 6
[post_date] => 2021-05-28 13:48:32
[post_date_gmt] => 2021-05-28 13:48:32
[post_content] =>
[post_title] => UK Secretary of State - AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:12:31
[post_modified_gmt] => 2021-09-15 12:12:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2943
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 2817
[post_author] => 5
[post_date] => 2021-04-16 11:58:45
[post_date_gmt] => 2021-04-16 11:58:45
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-23 06:24:06
[post_modified_gmt] => 2022-06-23 06:24:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2817
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 3776
[post_author] => 5
[post_date] => 2021-09-09 11:24:04
[post_date_gmt] => 2021-09-09 11:24:04
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:12:55
[post_modified_gmt] => 2021-09-15 12:12:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=3776
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 2446
[post_author] => 5
[post_date] => 2021-01-19 09:42:42
[post_date_gmt] => 2021-01-19 09:42:42
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => award-contract-no-w911qy20c0100-by-and-between-modernatx-inc-and-the-department-of-defense
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:03:43
[post_modified_gmt] => 2021-09-15 12:03:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2446
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 2732
[post_author] => 5
[post_date] => 2021-03-23 15:54:07
[post_date_gmt] => 2021-03-23 15:54:07
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-statement-of-work-for-rapid-wf10-advanced-research-development-to-large-scale-manufacturing-of-nvx-cov-2373-as-a-vaccine-for-sars-cov-2-coronavirus-under-the-base-agreemen
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:18:39
[post_modified_gmt] => 2021-09-15 12:18:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2732
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 2455
[post_author] => 5
[post_date] => 2021-02-25 15:19:51
[post_date_gmt] => 2021-02-25 15:19:51
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:13:19
[post_modified_gmt] => 2021-09-15 12:13:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2455
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 27
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 2438
[post_author] => 5
[post_date] => 2021-01-19 06:43:39
[post_date_gmt] => 2021-01-19 06:43:39
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-agreement-contract-no-75a50122c00034-for-development-of-an-mrna-vaccine-for-sars-cov-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-15 12:05:25
[post_modified_gmt] => 2021-09-15 12:05:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=agreement&p=2438
[menu_order] => 0
[post_type] => agreement
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 27
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => 1fc2d19f378284cf7496bf5ba612c2e6
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[text_provision_q_rslts] => WP_Query Object
(
[query] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
)
[query_vars] => Array
(
[post_type] => provision_document
[posts_per_page] => -1
[s] => covid 19
[error] =>
[m] =>
[p] => 0
[post_parent] =>
[subpost] =>
[subpost_id] =>
[attachment] =>
[attachment_id] => 0
[name] =>
[pagename] =>
[page_id] => 0
[second] =>
[minute] =>
[hour] =>
[day] => 0
[monthnum] => 0
[year] => 0
[w] => 0
[category_name] =>
[tag] =>
[cat] =>
[tag_id] =>
[author] =>
[author_name] =>
[feed] =>
[tb] =>
[paged] => 0
[meta_key] =>
[meta_value] =>
[preview] =>
[sentence] =>
[title] =>
[fields] =>
[menu_order] =>
[embed] =>
[category__in] => Array
(
)
[category__not_in] => Array
(
)
[category__and] => Array
(
)
[post__in] => Array
(
)
[post__not_in] => Array
(
)
[post_name__in] => Array
(
)
[tag__in] => Array
(
)
[tag__not_in] => Array
(
)
[tag__and] => Array
(
)
[tag_slug__in] => Array
(
)
[tag_slug__and] => Array
(
)
[post_parent__in] => Array
(
)
[post_parent__not_in] => Array
(
)
[author__in] => Array
(
)
[author__not_in] => Array
(
)
[suppress_filters] =>
[ignore_sticky_posts] =>
[cache_results] => 1
[update_post_term_cache] => 1
[lazy_load_term_meta] => 1
[update_post_meta_cache] => 1
[nopaging] => 1
[comments_per_page] => 50
[no_found_rows] =>
[search_terms_count] => 2
[search_terms] => Array
(
[0] => covid
[1] => 19
)
[search_orderby_title] => Array
(
[0] => wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}covid{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}'
[1] => wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}19{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}'
)
[order] => DESC
)
[tax_query] => WP_Tax_Query Object
(
[queries] => Array
(
)
[relation] => AND
[table_aliases:protected] => Array
(
)
[queried_terms] => Array
(
)
[primary_table] => wpry_posts
[primary_id_column] => ID
)
[meta_query] => WP_Meta_Query Object
(
[queries] => Array
(
)
[relation] =>
[meta_table] =>
[meta_id_column] =>
[primary_table] =>
[primary_id_column] =>
[table_aliases:protected] => Array
(
)
[clauses:protected] => Array
(
)
[has_or_relation:protected] =>
)
[date_query] =>
[request] =>
SELECT DISTINCT wpry_posts.*
FROM wpry_posts INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) )
WHERE 1=1 AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%covid%' ) AND ( a.meta_value LIKE '%19%' ) ) OR ( ( ( wpry_posts.post_title LIKE '%covid%' ) OR ( wpry_posts.post_content LIKE '%covid%' ) OR ( wpry_posts.post_excerpt LIKE '%covid%' ) ) AND ( ( wpry_posts.post_title LIKE '%19%' ) OR ( wpry_posts.post_content LIKE '%19%' ) OR ( wpry_posts.post_excerpt LIKE '%19%' ) ) ) ) AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
ORDER BY (CASE WHEN wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}covid 19{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}' THEN 1 WHEN wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}covid{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}' AND wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}19{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}' THEN 2 WHEN wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}covid{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}' OR wpry_posts.post_title LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}19{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}' THEN 3 WHEN wpry_posts.post_excerpt LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}covid 19{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}' THEN 4 WHEN wpry_posts.post_content LIKE '{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}covid 19{e07924d2d636f0486410f666e222eb3bed8512eb604ff17c344b1572b80525b8}' THEN 5 ELSE 6 END), wpry_posts.post_date DESC
[posts] => Array
(
[0] => WP_Post Object
(
[ID] => 5782
[post_author] => 5
[post_date] => 2022-09-16 07:28:56
[post_date_gmt] => 2022-09-16 07:28:56
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 08:33:07
[post_modified_gmt] => 2022-09-26 08:33:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 5653
[post_author] => 5
[post_date] => 2022-08-25 12:56:30
[post_date_gmt] => 2022-08-25 12:56:30
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-25 12:56:30
[post_modified_gmt] => 2022-08-25 12:56:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5653
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 5652
[post_author] => 5
[post_date] => 2022-08-25 12:26:53
[post_date_gmt] => 2022-08-25 12:26:53
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-25 12:26:53
[post_modified_gmt] => 2022-08-25 12:26:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5652
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 5620
[post_author] => 5
[post_date] => 2022-08-12 12:05:12
[post_date_gmt] => 2022-08-12 12:05:12
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 12:05:12
[post_modified_gmt] => 2022-08-12 12:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5620
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 5619
[post_author] => 5
[post_date] => 2022-08-12 12:02:21
[post_date_gmt] => 2022-08-12 12:02:21
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 12:02:21
[post_modified_gmt] => 2022-08-12 12:02:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5619
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 5618
[post_author] => 5
[post_date] => 2022-08-12 11:52:17
[post_date_gmt] => 2022-08-12 11:52:17
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:52:17
[post_modified_gmt] => 2022-08-12 11:52:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5618
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 5617
[post_author] => 5
[post_date] => 2022-08-12 11:49:46
[post_date_gmt] => 2022-08-12 11:49:46
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:49:46
[post_modified_gmt] => 2022-08-12 11:49:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5617
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 5616
[post_author] => 5
[post_date] => 2022-08-12 11:45:22
[post_date_gmt] => 2022-08-12 11:45:22
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:45:22
[post_modified_gmt] => 2022-08-12 11:45:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5616
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 5615
[post_author] => 5
[post_date] => 2022-08-12 11:40:08
[post_date_gmt] => 2022-08-12 11:40:08
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:40:08
[post_modified_gmt] => 2022-08-12 11:40:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5615
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 5614
[post_author] => 5
[post_date] => 2022-08-12 11:34:41
[post_date_gmt] => 2022-08-12 11:34:41
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:28:05
[post_modified_gmt] => 2022-09-29 11:28:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5614
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 5612
[post_author] => 5
[post_date] => 2022-08-12 10:14:31
[post_date_gmt] => 2022-08-12 10:14:31
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 10:48:37
[post_modified_gmt] => 2022-08-12 10:48:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5612
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 5611
[post_author] => 5
[post_date] => 2022-08-12 10:05:33
[post_date_gmt] => 2022-08-12 10:05:33
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 10:05:33
[post_modified_gmt] => 2022-08-12 10:05:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5611
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 5610
[post_author] => 5
[post_date] => 2022-08-12 09:31:00
[post_date_gmt] => 2022-08-12 09:31:00
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 09:31:00
[post_modified_gmt] => 2022-08-12 09:31:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5610
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 5609
[post_author] => 5
[post_date] => 2022-08-12 09:24:43
[post_date_gmt] => 2022-08-12 09:24:43
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 09:24:43
[post_modified_gmt] => 2022-08-12 09:24:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5609
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 5608
[post_author] => 5
[post_date] => 2022-08-12 09:09:54
[post_date_gmt] => 2022-08-12 09:09:54
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-23 13:54:19
[post_modified_gmt] => 2022-09-23 13:54:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5608
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 5599
[post_author] => 5
[post_date] => 2022-08-11 14:17:45
[post_date_gmt] => 2022-08-11 14:17:45
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 12:29:33
[post_modified_gmt] => 2022-08-12 12:29:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5599
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 5596
[post_author] => 5
[post_date] => 2022-08-11 12:52:07
[post_date_gmt] => 2022-08-11 12:52:07
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:52:07
[post_modified_gmt] => 2022-08-11 12:52:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5596
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 5595
[post_author] => 5
[post_date] => 2022-08-11 12:36:15
[post_date_gmt] => 2022-08-11 12:36:15
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:36:15
[post_modified_gmt] => 2022-08-11 12:36:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5595
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 5594
[post_author] => 5
[post_date] => 2022-08-11 12:13:32
[post_date_gmt] => 2022-08-11 12:13:32
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:46:35
[post_modified_gmt] => 2022-08-11 12:46:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5594
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 5593
[post_author] => 5
[post_date] => 2022-08-11 11:48:52
[post_date_gmt] => 2022-08-11 11:48:52
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:26:53
[post_modified_gmt] => 2022-08-11 12:26:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5593
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 5592
[post_author] => 5
[post_date] => 2022-08-11 11:16:19
[post_date_gmt] => 2022-08-11 11:16:19
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-23 13:53:40
[post_modified_gmt] => 2022-09-23 13:53:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5592
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 5591
[post_author] => 5
[post_date] => 2022-08-11 10:18:46
[post_date_gmt] => 2022-08-11 10:18:46
[post_content] =>
[post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 10:18:46
[post_modified_gmt] => 2022-08-11 10:18:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5591
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 5429
[post_author] => 5
[post_date] => 2022-07-25 06:51:00
[post_date_gmt] => 2022-07-25 06:51:00
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-25 07:15:14
[post_modified_gmt] => 2022-07-25 07:15:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5429
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 5123
[post_author] => 5
[post_date] => 2022-06-29 15:28:35
[post_date_gmt] => 2022-06-29 15:28:35
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 15:28:35
[post_modified_gmt] => 2022-06-29 15:28:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 5122
[post_author] => 5
[post_date] => 2022-06-29 14:42:34
[post_date_gmt] => 2022-06-29 14:42:34
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 5122
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-11 07:17:38
[post_modified_gmt] => 2022-07-11 07:17:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 5121
[post_author] => 5
[post_date] => 2022-06-29 14:38:19
[post_date_gmt] => 2022-06-29 14:38:19
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:30:17
[post_modified_gmt] => 2022-09-27 09:30:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 5120
[post_author] => 5
[post_date] => 2022-06-29 14:30:21
[post_date_gmt] => 2022-06-29 14:30:21
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:30:21
[post_modified_gmt] => 2022-06-29 14:30:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 5119
[post_author] => 5
[post_date] => 2022-06-29 14:09:28
[post_date_gmt] => 2022-06-29 14:09:28
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:09:28
[post_modified_gmt] => 2022-06-29 14:09:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 5118
[post_author] => 5
[post_date] => 2022-06-29 14:05:52
[post_date_gmt] => 2022-06-29 14:05:52
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:05:52
[post_modified_gmt] => 2022-06-29 14:05:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5118
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 5117
[post_author] => 5
[post_date] => 2022-06-29 14:02:42
[post_date_gmt] => 2022-06-29 14:02:42
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:02:42
[post_modified_gmt] => 2022-06-29 14:02:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 5116
[post_author] => 5
[post_date] => 2022-06-29 14:00:58
[post_date_gmt] => 2022-06-29 14:00:58
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:00:58
[post_modified_gmt] => 2022-06-29 14:00:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5116
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 5115
[post_author] => 5
[post_date] => 2022-06-29 13:52:08
[post_date_gmt] => 2022-06-29 13:52:08
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 13:52:08
[post_modified_gmt] => 2022-06-29 13:52:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5115
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 5114
[post_author] => 5
[post_date] => 2022-06-29 13:46:01
[post_date_gmt] => 2022-06-29 13:46:01
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 15:10:31
[post_modified_gmt] => 2022-06-29 15:10:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5114
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 5113
[post_author] => 5
[post_date] => 2022-06-29 13:33:56
[post_date_gmt] => 2022-06-29 13:33:56
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-11 08:34:58
[post_modified_gmt] => 2022-07-11 08:34:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 5112
[post_author] => 5
[post_date] => 2022-06-29 13:04:55
[post_date_gmt] => 2022-06-29 13:04:55
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:33:12
[post_modified_gmt] => 2022-07-13 13:33:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5112
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 5111
[post_author] => 5
[post_date] => 2022-06-29 12:40:35
[post_date_gmt] => 2022-06-29 12:40:35
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:47:17
[post_modified_gmt] => 2022-07-13 10:47:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5111
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:49:36
[post_modified_gmt] => 2022-09-26 14:49:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 4807
[post_author] => 5
[post_date] => 2022-05-24 09:02:55
[post_date_gmt] => 2022-05-24 09:02:55
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:02:55
[post_modified_gmt] => 2022-05-24 09:02:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 4806
[post_author] => 5
[post_date] => 2022-05-24 08:59:08
[post_date_gmt] => 2022-05-24 08:59:08
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:08
[post_modified_gmt] => 2022-05-24 08:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 4805
[post_author] => 5
[post_date] => 2022-05-24 08:53:12
[post_date_gmt] => 2022-05-24 08:53:12
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:42
[post_modified_gmt] => 2022-05-24 08:59:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 4804
[post_author] => 5
[post_date] => 2022-05-24 08:40:15
[post_date_gmt] => 2022-05-24 08:40:15
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:53:51
[post_modified_gmt] => 2022-05-24 08:53:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 4802
[post_author] => 5
[post_date] => 2022-05-24 08:24:23
[post_date_gmt] => 2022-05-24 08:24:23
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:24:23
[post_modified_gmt] => 2022-05-24 08:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 4801
[post_author] => 5
[post_date] => 2022-05-24 08:19:21
[post_date_gmt] => 2022-05-24 08:19:21
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:19:21
[post_modified_gmt] => 2022-05-24 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 4800
[post_author] => 5
[post_date] => 2022-05-24 08:07:39
[post_date_gmt] => 2022-05-24 08:07:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:08:30
[post_modified_gmt] => 2022-05-24 08:08:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 4797
[post_author] => 5
[post_date] => 2022-05-23 13:54:57
[post_date_gmt] => 2022-05-23 13:54:57
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:28:31
[post_modified_gmt] => 2022-07-13 12:28:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 4796
[post_author] => 5
[post_date] => 2022-05-23 13:54:05
[post_date_gmt] => 2022-05-23 13:54:05
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-17 13:44:36
[post_modified_gmt] => 2022-06-17 13:44:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 4661
[post_author] => 5
[post_date] => 2022-04-20 08:13:06
[post_date_gmt] => 2022-04-20 08:13:06
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:31:12
[post_modified_gmt] => 2022-09-27 09:31:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4661
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:22:54
[post_modified_gmt] => 2022-04-18 13:22:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 4601
[post_author] => 5
[post_date] => 2022-04-18 10:40:48
[post_date_gmt] => 2022-04-18 10:40:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:44:46
[post_modified_gmt] => 2022-04-18 10:44:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4601
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:11:50
[post_modified_gmt] => 2022-07-06 10:11:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 4223
[post_author] => 5
[post_date] => 2022-03-04 09:43:58
[post_date_gmt] => 2022-03-04 09:43:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 18:00:18
[post_modified_gmt] => 2022-05-31 18:00:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 4222
[post_author] => 5
[post_date] => 2022-03-04 09:14:41
[post_date_gmt] => 2022-03-04 09:14:41
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:59:19
[post_modified_gmt] => 2022-05-31 17:59:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 4221
[post_author] => 5
[post_date] => 2022-03-04 09:05:29
[post_date_gmt] => 2022-03-04 09:05:29
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:36:15
[post_modified_gmt] => 2022-09-26 14:36:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 4220
[post_author] => 5
[post_date] => 2022-03-04 08:47:04
[post_date_gmt] => 2022-03-04 08:47:04
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:08:10
[post_modified_gmt] => 2022-05-31 15:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 4219
[post_author] => 5
[post_date] => 2022-03-04 08:02:15
[post_date_gmt] => 2022-03-04 08:02:15
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:57:38
[post_modified_gmt] => 2022-05-31 17:57:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 4218
[post_author] => 5
[post_date] => 2022-03-03 14:17:53
[post_date_gmt] => 2022-03-03 14:17:53
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:57:06
[post_modified_gmt] => 2022-05-31 17:57:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4217
[post_author] => 5
[post_date] => 2022-03-03 13:59:58
[post_date_gmt] => 2022-03-03 13:59:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:43
[post_modified_gmt] => 2022-05-31 17:56:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4216
[post_author] => 5
[post_date] => 2022-03-03 13:45:21
[post_date_gmt] => 2022-03-03 13:45:21
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:00
[post_modified_gmt] => 2022-05-31 17:56:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4215
[post_author] => 5
[post_date] => 2022-03-03 13:31:56
[post_date_gmt] => 2022-03-03 13:31:56
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:41:55
[post_modified_gmt] => 2022-09-29 10:41:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-19 13:44:17
[post_modified_gmt] => 2022-07-19 13:44:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:05:32
[post_modified_gmt] => 2022-05-31 15:05:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 4212
[post_author] => 5
[post_date] => 2022-03-02 14:54:16
[post_date_gmt] => 2022-03-02 14:54:16
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:54:11
[post_modified_gmt] => 2022-05-31 17:54:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4212
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 4210
[post_author] => 5
[post_date] => 2022-03-02 13:14:31
[post_date_gmt] => 2022-03-02 13:14:31
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:03:49
[post_modified_gmt] => 2022-07-13 12:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 4209
[post_author] => 5
[post_date] => 2022-03-02 12:07:13
[post_date_gmt] => 2022-03-02 12:07:13
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:12:02
[post_modified_gmt] => 2022-07-13 09:12:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4209
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 4205
[post_author] => 5
[post_date] => 2022-02-28 15:24:19
[post_date_gmt] => 2022-02-28 15:24:19
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 15:24:19
[post_modified_gmt] => 2022-02-28 15:24:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 4204
[post_author] => 5
[post_date] => 2022-02-28 14:53:11
[post_date_gmt] => 2022-02-28 14:53:11
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:53:11
[post_modified_gmt] => 2022-02-28 14:53:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 4201
[post_author] => 5
[post_date] => 2022-02-28 13:33:22
[post_date_gmt] => 2022-02-28 13:33:22
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-25 12:24:19
[post_modified_gmt] => 2022-08-25 12:24:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 4200
[post_author] => 5
[post_date] => 2022-02-28 13:13:29
[post_date_gmt] => 2022-02-28 13:13:29
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-15 14:39:30
[post_modified_gmt] => 2022-09-15 14:39:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:17:00
[post_modified_gmt] => 2022-04-18 13:17:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 4159
[post_author] => 5
[post_date] => 2022-02-02 13:10:48
[post_date_gmt] => 2022-02-02 13:10:48
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:16:05
[post_modified_gmt] => 2022-04-18 13:16:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 4158
[post_author] => 5
[post_date] => 2022-02-02 13:00:08
[post_date_gmt] => 2022-02-02 13:00:08
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:15:30
[post_modified_gmt] => 2022-04-18 13:15:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 4157
[post_author] => 5
[post_date] => 2022-02-02 12:54:56
[post_date_gmt] => 2022-02-02 12:54:56
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:13:37
[post_modified_gmt] => 2022-04-18 13:13:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 4156
[post_author] => 5
[post_date] => 2022-02-02 12:36:42
[post_date_gmt] => 2022-02-02 12:36:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:51
[post_modified_gmt] => 2022-04-18 13:12:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 4155
[post_author] => 5
[post_date] => 2022-02-02 12:19:16
[post_date_gmt] => 2022-02-02 12:19:16
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:26
[post_modified_gmt] => 2022-04-18 13:12:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 4154
[post_author] => 5
[post_date] => 2022-02-02 12:13:41
[post_date_gmt] => 2022-02-02 12:13:41
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 12:13:41
[post_modified_gmt] => 2022-02-02 12:13:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4154
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 4153
[post_author] => 5
[post_date] => 2022-02-02 12:10:13
[post_date_gmt] => 2022-02-02 12:10:13
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:28:28
[post_modified_gmt] => 2022-09-29 11:28:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4153
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 4152
[post_author] => 5
[post_date] => 2022-02-02 11:51:54
[post_date_gmt] => 2022-02-02 11:51:54
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:57:07
[post_modified_gmt] => 2022-09-26 14:57:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 4151
[post_author] => 5
[post_date] => 2022-02-02 11:39:24
[post_date_gmt] => 2022-02-02 11:39:24
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:35
[post_modified_gmt] => 2022-04-18 13:01:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:03
[post_modified_gmt] => 2022-04-18 13:01:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:00:34
[post_modified_gmt] => 2022-04-18 13:00:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 4146
[post_author] => 5
[post_date] => 2022-02-02 07:28:42
[post_date_gmt] => 2022-02-02 07:28:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:45:36
[post_modified_gmt] => 2022-07-13 09:45:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4146
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 4141
[post_author] => 5
[post_date] => 2022-01-31 14:31:23
[post_date_gmt] => 2022-01-31 14:31:23
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:33:23
[post_modified_gmt] => 2022-01-31 14:33:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 4140
[post_author] => 5
[post_date] => 2022-01-31 14:22:03
[post_date_gmt] => 2022-01-31 14:22:03
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:11:05
[post_modified_gmt] => 2022-03-09 13:11:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 4139
[post_author] => 5
[post_date] => 2022-01-31 14:18:32
[post_date_gmt] => 2022-01-31 14:18:32
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:48:21
[post_modified_gmt] => 2022-09-26 14:48:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 4138
[post_author] => 5
[post_date] => 2022-01-31 14:09:33
[post_date_gmt] => 2022-01-31 14:09:33
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:09:33
[post_modified_gmt] => 2022-01-31 14:09:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4138
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 4137
[post_author] => 5
[post_date] => 2022-01-31 13:53:37
[post_date_gmt] => 2022-01-31 13:53:37
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:54:45
[post_modified_gmt] => 2022-01-31 13:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 4136
[post_author] => 5
[post_date] => 2022-01-31 13:42:47
[post_date_gmt] => 2022-01-31 13:42:47
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:42:47
[post_modified_gmt] => 2022-01-31 13:42:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 4135
[post_author] => 5
[post_date] => 2022-01-31 13:25:08
[post_date_gmt] => 2022-01-31 13:25:08
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:25:08
[post_modified_gmt] => 2022-01-31 13:25:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 4134
[post_author] => 5
[post_date] => 2022-01-31 12:56:28
[post_date_gmt] => 2022-01-31 12:56:28
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:52:57
[post_modified_gmt] => 2022-09-29 10:52:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:24:36
[post_modified_gmt] => 2022-01-31 12:24:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 16:31:13
[post_modified_gmt] => 2022-01-29 16:31:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 4130
[post_author] => 5
[post_date] => 2022-01-29 15:34:50
[post_date_gmt] => 2022-01-29 15:34:50
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 15:49:57
[post_modified_gmt] => 2022-01-29 15:49:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 4129
[post_author] => 5
[post_date] => 2022-01-28 14:43:06
[post_date_gmt] => 2022-01-28 14:43:06
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 09:58:49
[post_modified_gmt] => 2022-07-06 09:58:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:45:11
[post_modified_gmt] => 2022-01-28 13:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 4058
[post_author] => 5
[post_date] => 2022-01-04 14:25:52
[post_date_gmt] => 2022-01-04 14:25:52
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:25:52
[post_modified_gmt] => 2022-01-04 14:25:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4058
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 4054
[post_author] => 5
[post_date] => 2022-01-03 11:45:52
[post_date_gmt] => 2022-01-03 11:45:52
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 11:46:09
[post_modified_gmt] => 2022-01-03 11:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4054
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 4051
[post_author] => 5
[post_date] => 2022-01-03 11:01:41
[post_date_gmt] => 2022-01-03 11:01:41
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 10:37:08
[post_modified_gmt] => 2022-03-09 10:37:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 4050
[post_author] => 5
[post_date] => 2022-01-03 10:49:32
[post_date_gmt] => 2022-01-03 10:49:32
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:56:55
[post_modified_gmt] => 2022-01-03 10:56:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4050
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 4047
[post_author] => 5
[post_date] => 2021-12-27 17:17:36
[post_date_gmt] => 2021-12-27 17:17:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:43:10
[post_modified_gmt] => 2022-01-03 10:43:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4047
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 4046
[post_author] => 5
[post_date] => 2021-12-27 17:10:47
[post_date_gmt] => 2021-12-27 17:10:47
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:10:47
[post_modified_gmt] => 2021-12-27 17:10:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4046
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 4045
[post_author] => 5
[post_date] => 2021-12-27 17:07:25
[post_date_gmt] => 2021-12-27 17:07:25
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:07:25
[post_modified_gmt] => 2021-12-27 17:07:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4045
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 4043
[post_author] => 5
[post_date] => 2021-12-27 16:47:54
[post_date_gmt] => 2021-12-27 16:47:54
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:47:54
[post_modified_gmt] => 2021-12-27 16:47:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4043
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 4042
[post_author] => 5
[post_date] => 2021-12-27 16:41:56
[post_date_gmt] => 2021-12-27 16:41:56
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:25:56
[post_modified_gmt] => 2022-09-29 12:25:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4042
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 4041
[post_author] => 5
[post_date] => 2021-12-27 16:28:21
[post_date_gmt] => 2021-12-27 16:28:21
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:28:42
[post_modified_gmt] => 2021-12-27 16:28:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4041
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 4040
[post_author] => 5
[post_date] => 2021-12-27 15:24:04
[post_date_gmt] => 2021-12-27 15:24:04
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-14 12:58:21
[post_modified_gmt] => 2022-03-14 12:58:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 4038
[post_author] => 5
[post_date] => 2021-12-27 15:08:30
[post_date_gmt] => 2021-12-27 15:08:30
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:22:28
[post_modified_gmt] => 2022-01-24 12:22:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4038
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 4036
[post_author] => 5
[post_date] => 2021-12-26 17:01:45
[post_date_gmt] => 2021-12-26 17:01:45
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:46:09
[post_modified_gmt] => 2022-09-27 09:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4036
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 4035
[post_author] => 5
[post_date] => 2021-12-26 16:47:36
[post_date_gmt] => 2021-12-26 16:47:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-26 16:47:36
[post_modified_gmt] => 2021-12-26 16:47:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4035
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 4032
[post_author] => 5
[post_date] => 2021-12-26 16:32:27
[post_date_gmt] => 2021-12-26 16:32:27
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-22 14:37:29
[post_modified_gmt] => 2022-01-22 14:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4032
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 4029
[post_author] => 5
[post_date] => 2021-12-21 12:22:08
[post_date_gmt] => 2021-12-21 12:22:08
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 14:31:07
[post_modified_gmt] => 2022-06-27 14:31:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4029
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 4028
[post_author] => 5
[post_date] => 2021-12-21 11:55:28
[post_date_gmt] => 2021-12-21 11:55:28
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 11:03:21
[post_modified_gmt] => 2022-07-13 11:03:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4028
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 4024
[post_author] => 5
[post_date] => 2021-12-15 15:33:17
[post_date_gmt] => 2021-12-15 15:33:17
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 15:33:17
[post_modified_gmt] => 2021-12-15 15:33:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4024
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 4022
[post_author] => 5
[post_date] => 2021-12-15 14:49:36
[post_date_gmt] => 2021-12-15 14:49:36
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:51:23
[post_modified_gmt] => 2021-12-15 14:51:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4022
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 4021
[post_author] => 5
[post_date] => 2021-12-15 14:31:00
[post_date_gmt] => 2021-12-15 14:31:00
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:31:00
[post_modified_gmt] => 2021-12-15 14:31:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4021
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 4020
[post_author] => 5
[post_date] => 2021-12-15 14:24:47
[post_date_gmt] => 2021-12-15 14:24:47
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:24:47
[post_modified_gmt] => 2021-12-15 14:24:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4020
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 4017
[post_author] => 5
[post_date] => 2021-12-15 13:22:49
[post_date_gmt] => 2021-12-15 13:22:49
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 13:22:49
[post_modified_gmt] => 2021-12-15 13:22:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4017
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 4016
[post_author] => 5
[post_date] => 2021-12-15 13:20:07
[post_date_gmt] => 2021-12-15 13:20:07
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:54:29
[post_modified_gmt] => 2022-09-29 10:54:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4016
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 4014
[post_author] => 5
[post_date] => 2021-12-15 12:33:09
[post_date_gmt] => 2021-12-15 12:33:09
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:33:09
[post_modified_gmt] => 2021-12-15 12:33:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4014
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 4013
[post_author] => 5
[post_date] => 2021-12-15 12:16:20
[post_date_gmt] => 2021-12-15 12:16:20
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:17:01
[post_modified_gmt] => 2021-12-15 12:17:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4013
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 4011
[post_author] => 5
[post_date] => 2021-12-14 15:21:54
[post_date_gmt] => 2021-12-14 15:21:54
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:25:12
[post_modified_gmt] => 2022-07-13 09:25:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4011
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 4009
[post_author] => 5
[post_date] => 2021-12-14 15:10:51
[post_date_gmt] => 2021-12-14 15:10:51
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:00:07
[post_modified_gmt] => 2022-03-09 11:00:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4009
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 4007
[post_author] => 5
[post_date] => 2021-12-14 08:51:32
[post_date_gmt] => 2021-12-14 08:51:32
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 08:51:44
[post_modified_gmt] => 2021-12-14 08:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4007
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 4006
[post_author] => 5
[post_date] => 2021-12-14 08:16:01
[post_date_gmt] => 2021-12-14 08:16:01
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 14:46:11
[post_modified_gmt] => 2022-03-23 14:46:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4006
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 4004
[post_author] => 5
[post_date] => 2021-12-14 07:57:41
[post_date_gmt] => 2021-12-14 07:57:41
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 07:57:41
[post_modified_gmt] => 2021-12-14 07:57:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4004
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 4003
[post_author] => 5
[post_date] => 2021-12-13 18:36:53
[post_date_gmt] => 2021-12-13 18:36:53
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:50:30
[post_modified_gmt] => 2022-09-26 14:50:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4003
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 4002
[post_author] => 5
[post_date] => 2021-12-13 18:28:05
[post_date_gmt] => 2021-12-13 18:28:05
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:41:28
[post_modified_gmt] => 2021-12-13 18:41:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4002
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 3997
[post_author] => 5
[post_date] => 2021-12-13 14:24:49
[post_date_gmt] => 2021-12-13 14:24:49
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:52:42
[post_modified_gmt] => 2022-07-13 12:52:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3997
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 3869
[post_author] => 5
[post_date] => 2021-11-19 12:55:06
[post_date_gmt] => 2021-11-19 12:55:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:09:23
[post_modified_gmt] => 2022-07-13 10:09:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 3886
[post_author] => 5
[post_date] => 2021-11-18 16:36:37
[post_date_gmt] => 2021-11-18 16:36:37
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 06:09:26
[post_modified_gmt] => 2022-04-12 06:09:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3886
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 3884
[post_author] => 5
[post_date] => 2021-11-18 16:17:51
[post_date_gmt] => 2021-11-18 16:17:51
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:17:21
[post_modified_gmt] => 2022-03-09 11:17:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3884
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 3883
[post_author] => 5
[post_date] => 2021-11-18 16:10:24
[post_date_gmt] => 2021-11-18 16:10:24
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:48:26
[post_modified_gmt] => 2021-12-03 12:48:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3883
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 3882
[post_author] => 5
[post_date] => 2021-11-18 16:01:06
[post_date_gmt] => 2021-11-18 16:01:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:49:07
[post_modified_gmt] => 2021-12-03 12:49:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3882
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 3881
[post_author] => 5
[post_date] => 2021-11-18 15:52:45
[post_date_gmt] => 2021-11-18 15:52:45
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:52:45
[post_modified_gmt] => 2021-11-18 15:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3881
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 3880
[post_author] => 5
[post_date] => 2021-11-18 15:50:26
[post_date_gmt] => 2021-11-18 15:50:26
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:50:26
[post_modified_gmt] => 2021-11-18 15:50:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3880
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 3878
[post_author] => 5
[post_date] => 2021-11-18 15:08:19
[post_date_gmt] => 2021-11-18 15:08:19
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:08:19
[post_modified_gmt] => 2021-11-18 15:08:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3878
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 3877
[post_author] => 5
[post_date] => 2021-11-18 15:05:16
[post_date_gmt] => 2021-11-18 15:05:16
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:45:57
[post_modified_gmt] => 2022-09-29 11:45:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 3876
[post_author] => 5
[post_date] => 2021-11-18 14:51:40
[post_date_gmt] => 2021-11-18 14:51:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 14:51:40
[post_modified_gmt] => 2021-11-18 14:51:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3876
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 3875
[post_author] => 5
[post_date] => 2021-11-18 14:43:39
[post_date_gmt] => 2021-11-18 14:43:39
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 10:50:23
[post_modified_gmt] => 2021-11-22 10:50:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3875
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 3874
[post_author] => 5
[post_date] => 2021-11-18 14:29:06
[post_date_gmt] => 2021-11-18 14:29:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 08:08:10
[post_modified_gmt] => 2022-04-12 08:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3874
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 3873
[post_author] => 5
[post_date] => 2021-11-18 14:05:12
[post_date_gmt] => 2021-11-18 14:05:12
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:22:45
[post_modified_gmt] => 2021-11-19 12:22:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 3870
[post_author] => 5
[post_date] => 2021-11-18 12:58:35
[post_date_gmt] => 2021-11-18 12:58:35
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:14:06
[post_modified_gmt] => 2022-07-13 13:14:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 3863
[post_author] => 5
[post_date] => 2021-11-05 14:19:38
[post_date_gmt] => 2021-11-05 14:19:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:42
[post_modified_gmt] => 2022-04-18 09:22:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3863
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 3861
[post_author] => 5
[post_date] => 2021-11-05 13:59:54
[post_date_gmt] => 2021-11-05 13:59:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:26
[post_modified_gmt] => 2022-04-18 07:16:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3861
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 3860
[post_author] => 5
[post_date] => 2021-11-05 13:51:48
[post_date_gmt] => 2021-11-05 13:51:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:48
[post_modified_gmt] => 2022-04-18 07:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3860
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 3859
[post_author] => 5
[post_date] => 2021-11-05 13:44:47
[post_date_gmt] => 2021-11-05 13:44:47
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:28:57
[post_modified_gmt] => 2022-04-18 07:28:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3859
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 3858
[post_author] => 5
[post_date] => 2021-11-05 13:39:37
[post_date_gmt] => 2021-11-05 13:39:37
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:54:11
[post_modified_gmt] => 2022-04-18 07:54:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3858
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 3857
[post_author] => 5
[post_date] => 2021-11-05 13:37:12
[post_date_gmt] => 2021-11-05 13:37:12
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:41:41
[post_modified_gmt] => 2022-04-18 07:41:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3857
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 3856
[post_author] => 5
[post_date] => 2021-11-05 13:12:38
[post_date_gmt] => 2021-11-05 13:12:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:54:20
[post_modified_gmt] => 2022-09-26 14:54:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3856
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 3855
[post_author] => 5
[post_date] => 2021-11-05 13:10:25
[post_date_gmt] => 2021-11-05 13:10:25
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:08:38
[post_modified_gmt] => 2022-07-06 10:08:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3855
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 3854
[post_author] => 5
[post_date] => 2021-11-05 13:03:41
[post_date_gmt] => 2021-11-05 13:03:41
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:15:00
[post_modified_gmt] => 2022-04-18 08:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3854
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 3852
[post_author] => 5
[post_date] => 2021-11-05 12:43:57
[post_date_gmt] => 2021-11-05 12:43:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:33:20
[post_modified_gmt] => 2022-04-18 08:33:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3852
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[152] => WP_Post Object
(
[ID] => 3851
[post_author] => 5
[post_date] => 2021-11-05 12:41:54
[post_date_gmt] => 2021-11-05 12:41:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:45:20
[post_modified_gmt] => 2022-04-18 08:45:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3851
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[153] => WP_Post Object
(
[ID] => 3849
[post_author] => 5
[post_date] => 2021-11-05 12:30:09
[post_date_gmt] => 2021-11-05 12:30:09
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:52:12
[post_modified_gmt] => 2022-04-18 08:52:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3849
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[154] => WP_Post Object
(
[ID] => 3848
[post_author] => 5
[post_date] => 2021-11-05 12:27:44
[post_date_gmt] => 2021-11-05 12:27:44
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:58:14
[post_modified_gmt] => 2022-04-18 08:58:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3848
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[155] => WP_Post Object
(
[ID] => 3847
[post_author] => 5
[post_date] => 2021-11-05 12:25:40
[post_date_gmt] => 2021-11-05 12:25:40
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:38:24
[post_modified_gmt] => 2022-07-13 09:38:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3847
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[156] => WP_Post Object
(
[ID] => 3846
[post_author] => 5
[post_date] => 2021-11-05 12:14:17
[post_date_gmt] => 2021-11-05 12:14:17
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:02:17
[post_modified_gmt] => 2022-07-13 13:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3846
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[157] => WP_Post Object
(
[ID] => 3819
[post_author] => 6
[post_date] => 2021-09-15 12:17:55
[post_date_gmt] => 2021-09-15 12:17:55
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:51:14
[post_modified_gmt] => 2022-07-13 12:51:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3819
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[158] => WP_Post Object
(
[ID] => 3812
[post_author] => 5
[post_date] => 2021-09-10 12:44:57
[post_date_gmt] => 2021-09-10 12:44:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:13:50
[post_modified_gmt] => 2022-04-20 09:13:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3812
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[159] => WP_Post Object
(
[ID] => 3810
[post_author] => 5
[post_date] => 2021-09-10 12:21:33
[post_date_gmt] => 2021-09-10 12:21:33
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:11:54
[post_modified_gmt] => 2022-04-20 07:11:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3810
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[160] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:19:45
[post_modified_gmt] => 2022-04-20 09:19:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[161] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:24:05
[post_modified_gmt] => 2022-04-20 07:24:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[162] => WP_Post Object
(
[ID] => 3807
[post_author] => 5
[post_date] => 2021-09-10 11:55:25
[post_date_gmt] => 2021-09-10 11:55:25
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:42:12
[post_modified_gmt] => 2022-04-20 07:42:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[163] => WP_Post Object
(
[ID] => 3806
[post_author] => 5
[post_date] => 2021-09-10 11:47:18
[post_date_gmt] => 2021-09-10 11:47:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:17:33
[post_modified_gmt] => 2022-07-06 10:17:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[164] => WP_Post Object
(
[ID] => 3805
[post_author] => 5
[post_date] => 2021-09-10 11:33:53
[post_date_gmt] => 2021-09-10 11:33:53
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:46:59
[post_modified_gmt] => 2022-04-20 07:46:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[165] => WP_Post Object
(
[ID] => 3804
[post_author] => 5
[post_date] => 2021-09-10 11:20:59
[post_date_gmt] => 2021-09-10 11:20:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:50:11
[post_modified_gmt] => 2022-04-20 07:50:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[166] => WP_Post Object
(
[ID] => 3803
[post_author] => 5
[post_date] => 2021-09-10 10:54:42
[post_date_gmt] => 2021-09-10 10:54:42
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:51:06
[post_modified_gmt] => 2022-04-20 07:51:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3803
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[167] => WP_Post Object
(
[ID] => 3802
[post_author] => 5
[post_date] => 2021-09-10 10:45:57
[post_date_gmt] => 2021-09-10 10:45:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:54:14
[post_modified_gmt] => 2022-04-20 07:54:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[168] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:05:17
[post_modified_gmt] => 2022-04-20 08:05:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[169] => WP_Post Object
(
[ID] => 3800
[post_author] => 5
[post_date] => 2021-09-10 10:25:59
[post_date_gmt] => 2021-09-10 10:25:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:35:52
[post_modified_gmt] => 2022-04-20 08:35:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[170] => WP_Post Object
(
[ID] => 3799
[post_author] => 5
[post_date] => 2021-09-10 10:07:18
[post_date_gmt] => 2021-09-10 10:07:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:44:40
[post_modified_gmt] => 2022-04-20 08:44:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3799
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[171] => WP_Post Object
(
[ID] => 3798
[post_author] => 5
[post_date] => 2021-09-10 10:02:07
[post_date_gmt] => 2021-09-10 10:02:07
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:35:06
[post_modified_gmt] => 2022-07-13 13:35:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[172] => WP_Post Object
(
[ID] => 3797
[post_author] => 5
[post_date] => 2021-09-10 09:54:44
[post_date_gmt] => 2021-09-10 09:54:44
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:57:55
[post_modified_gmt] => 2022-07-13 10:57:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[173] => WP_Post Object
(
[ID] => 3796
[post_author] => 5
[post_date] => 2021-09-10 09:03:43
[post_date_gmt] => 2021-09-10 09:03:43
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 13:10:22
[post_modified_gmt] => 2022-06-27 13:10:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[174] => WP_Post Object
(
[ID] => 3792
[post_author] => 5
[post_date] => 2021-09-09 14:23:13
[post_date_gmt] => 2021-09-09 14:23:13
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 12:44:33
[post_modified_gmt] => 2022-03-09 12:44:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3792
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[175] => WP_Post Object
(
[ID] => 3791
[post_author] => 5
[post_date] => 2021-09-09 14:18:44
[post_date_gmt] => 2021-09-09 14:18:44
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:00:35
[post_modified_gmt] => 2021-11-04 09:00:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3791
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[176] => WP_Post Object
(
[ID] => 3789
[post_author] => 5
[post_date] => 2021-09-09 14:07:30
[post_date_gmt] => 2021-09-09 14:07:30
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:32:36
[post_modified_gmt] => 2022-09-29 12:32:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3789
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[177] => WP_Post Object
(
[ID] => 3788
[post_author] => 5
[post_date] => 2021-09-09 14:00:40
[post_date_gmt] => 2021-09-09 14:00:40
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:02:12
[post_modified_gmt] => 2021-11-04 09:02:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3788
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[178] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:53:55
[post_modified_gmt] => 2022-05-27 08:53:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[179] => WP_Post Object
(
[ID] => 3785
[post_author] => 5
[post_date] => 2021-09-09 13:10:11
[post_date_gmt] => 2021-09-09 13:10:11
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:04:36
[post_modified_gmt] => 2021-11-04 09:04:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3785
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[180] => WP_Post Object
(
[ID] => 3784
[post_author] => 5
[post_date] => 2021-09-09 13:03:52
[post_date_gmt] => 2021-09-09 13:03:52
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:12
[post_modified_gmt] => 2021-11-04 09:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3784
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[181] => WP_Post Object
(
[ID] => 3783
[post_author] => 5
[post_date] => 2021-09-09 12:41:47
[post_date_gmt] => 2021-09-09 12:41:47
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:50
[post_modified_gmt] => 2021-11-04 09:05:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3783
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[182] => WP_Post Object
(
[ID] => 3782
[post_author] => 5
[post_date] => 2021-09-09 12:36:36
[post_date_gmt] => 2021-09-09 12:36:36
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-30 09:42:22
[post_modified_gmt] => 2022-08-30 09:42:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[183] => WP_Post Object
(
[ID] => 3781
[post_author] => 5
[post_date] => 2021-09-09 12:29:54
[post_date_gmt] => 2021-09-09 12:29:54
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:18:43
[post_modified_gmt] => 2021-11-23 14:18:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3781
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[184] => WP_Post Object
(
[ID] => 3778
[post_author] => 5
[post_date] => 2021-09-09 11:52:53
[post_date_gmt] => 2021-09-09 11:52:53
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:59:06
[post_modified_gmt] => 2022-09-27 09:59:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3778
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[185] => WP_Post Object
(
[ID] => 3765
[post_author] => 5
[post_date] => 2021-09-01 14:09:03
[post_date_gmt] => 2021-09-01 14:09:03
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:49:00
[post_modified_gmt] => 2022-03-28 10:49:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[186] => WP_Post Object
(
[ID] => 3764
[post_author] => 5
[post_date] => 2021-09-01 12:17:32
[post_date_gmt] => 2021-09-01 12:17:32
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:59:16
[post_modified_gmt] => 2022-09-26 14:59:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3764
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[187] => WP_Post Object
(
[ID] => 3758
[post_author] => 5
[post_date] => 2021-08-26 12:04:03
[post_date_gmt] => 2021-08-26 12:04:03
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:43:14
[post_modified_gmt] => 2022-03-28 10:43:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[188] => WP_Post Object
(
[ID] => 3741
[post_author] => 5
[post_date] => 2021-08-24 09:13:39
[post_date_gmt] => 2021-08-24 09:13:39
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:25:32
[post_modified_gmt] => 2022-09-26 14:25:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[189] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:46:20
[post_modified_gmt] => 2022-05-27 08:46:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[190] => WP_Post Object
(
[ID] => 3495
[post_author] => 5
[post_date] => 2021-08-10 13:06:45
[post_date_gmt] => 2021-08-10 13:06:45
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dod-moderna-covid-19-vaccine-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:12:04
[post_modified_gmt] => 2021-11-29 14:12:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3495
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[191] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 14:59:31
[post_modified_gmt] => 2022-08-12 14:59:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[192] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:25:22
[post_modified_gmt] => 2022-09-29 11:25:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[193] => WP_Post Object
(
[ID] => 3434
[post_author] => 6
[post_date] => 2021-07-01 03:44:18
[post_date_gmt] => 2021-07-01 03:44:18
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:28:59
[post_modified_gmt] => 2022-04-18 09:28:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3434
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[194] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:32:11
[post_modified_gmt] => 2022-04-18 09:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[195] => WP_Post Object
(
[ID] => 3431
[post_author] => 6
[post_date] => 2021-07-01 03:38:49
[post_date_gmt] => 2021-07-01 03:38:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:41:10
[post_modified_gmt] => 2022-04-18 09:41:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3431
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[196] => WP_Post Object
(
[ID] => 3430
[post_author] => 6
[post_date] => 2021-07-01 03:27:51
[post_date_gmt] => 2021-07-01 03:27:51
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:45:31
[post_modified_gmt] => 2022-04-18 09:45:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3430
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[197] => WP_Post Object
(
[ID] => 3428
[post_author] => 6
[post_date] => 2021-07-01 03:24:00
[post_date_gmt] => 2021-07-01 03:24:00
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:52:47
[post_modified_gmt] => 2022-09-26 14:52:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3428
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[198] => WP_Post Object
(
[ID] => 3427
[post_author] => 6
[post_date] => 2021-07-01 03:22:23
[post_date_gmt] => 2021-07-01 03:22:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:49:38
[post_modified_gmt] => 2022-04-18 09:49:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[199] => WP_Post Object
(
[ID] => 3426
[post_author] => 6
[post_date] => 2021-07-01 03:06:23
[post_date_gmt] => 2021-07-01 03:06:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:28:05
[post_modified_gmt] => 2022-04-18 10:28:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[200] => WP_Post Object
(
[ID] => 3424
[post_author] => 6
[post_date] => 2021-07-01 03:03:57
[post_date_gmt] => 2021-07-01 03:03:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:47:10
[post_modified_gmt] => 2022-04-18 10:47:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[201] => WP_Post Object
(
[ID] => 3422
[post_author] => 6
[post_date] => 2021-07-01 02:58:21
[post_date_gmt] => 2021-07-01 02:58:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-20 06:47:22
[post_modified_gmt] => 2022-06-20 06:47:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[202] => WP_Post Object
(
[ID] => 3421
[post_author] => 6
[post_date] => 2021-07-01 02:56:30
[post_date_gmt] => 2021-07-01 02:56:30
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:51:44
[post_modified_gmt] => 2022-04-18 10:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3421
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[203] => WP_Post Object
(
[ID] => 3420
[post_author] => 6
[post_date] => 2021-07-01 02:52:05
[post_date_gmt] => 2021-07-01 02:52:05
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:03:49
[post_modified_gmt] => 2022-07-06 10:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3420
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[204] => WP_Post Object
(
[ID] => 3372
[post_author] => 5
[post_date] => 2021-06-30 15:06:19
[post_date_gmt] => 2021-06-30 15:06:19
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:05:39
[post_modified_gmt] => 2022-03-09 13:05:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3372
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[205] => WP_Post Object
(
[ID] => 3370
[post_author] => 5
[post_date] => 2021-06-30 15:01:06
[post_date_gmt] => 2021-06-30 15:01:06
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:09:19
[post_modified_gmt] => 2022-09-29 12:09:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3370
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[206] => WP_Post Object
(
[ID] => 3368
[post_author] => 5
[post_date] => 2021-06-30 14:58:39
[post_date_gmt] => 2021-06-30 14:58:39
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:10:31
[post_modified_gmt] => 2021-08-24 08:10:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3368
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[207] => WP_Post Object
(
[ID] => 3366
[post_author] => 5
[post_date] => 2021-06-30 14:53:53
[post_date_gmt] => 2021-06-30 14:53:53
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:53:53
[post_modified_gmt] => 2021-06-30 14:53:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3366
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[208] => WP_Post Object
(
[ID] => 3364
[post_author] => 5
[post_date] => 2021-06-30 14:47:34
[post_date_gmt] => 2021-06-30 14:47:34
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-02 12:46:22
[post_modified_gmt] => 2021-09-02 12:46:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3364
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[209] => WP_Post Object
(
[ID] => 3361
[post_author] => 5
[post_date] => 2021-06-30 14:30:51
[post_date_gmt] => 2021-06-30 14:30:51
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:29:04
[post_modified_gmt] => 2022-07-13 13:29:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3361
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[210] => WP_Post Object
(
[ID] => 3360
[post_author] => 5
[post_date] => 2021-06-30 14:28:40
[post_date_gmt] => 2021-06-30 14:28:40
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:25:29
[post_modified_gmt] => 2022-09-27 09:25:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3360
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[211] => WP_Post Object
(
[ID] => 3356
[post_author] => 5
[post_date] => 2021-06-30 13:53:23
[post_date_gmt] => 2021-06-30 13:53:23
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:44:11
[post_modified_gmt] => 2022-03-28 10:44:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[212] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[213] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-08 12:52:45
[post_modified_gmt] => 2022-09-08 12:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[214] => WP_Post Object
(
[ID] => 3221
[post_author] => 6
[post_date] => 2021-06-28 12:23:49
[post_date_gmt] => 2021-06-28 12:23:49
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:47:45
[post_modified_gmt] => 2022-09-27 09:47:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[215] => WP_Post Object
(
[ID] => 3220
[post_author] => 6
[post_date] => 2021-06-28 12:22:09
[post_date_gmt] => 2021-06-28 12:22:09
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:08:44
[post_modified_gmt] => 2022-03-09 13:08:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[216] => WP_Post Object
(
[ID] => 3219
[post_author] => 6
[post_date] => 2021-06-28 12:19:29
[post_date_gmt] => 2021-06-28 12:19:29
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:28:41
[post_modified_gmt] => 2022-09-29 12:28:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[217] => WP_Post Object
(
[ID] => 3218
[post_author] => 6
[post_date] => 2021-06-28 12:16:20
[post_date_gmt] => 2021-06-28 12:16:20
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:37
[post_modified_gmt] => 2021-08-23 09:51:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[218] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:41
[post_modified_gmt] => 2021-08-23 09:51:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[219] => WP_Post Object
(
[ID] => 3216
[post_author] => 6
[post_date] => 2021-06-28 12:11:22
[post_date_gmt] => 2021-06-28 12:11:22
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:45
[post_modified_gmt] => 2021-08-23 09:51:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[220] => WP_Post Object
(
[ID] => 3215
[post_author] => 6
[post_date] => 2021-06-28 12:07:55
[post_date_gmt] => 2021-06-28 12:07:55
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 11:33:05
[post_modified_gmt] => 2022-07-13 11:33:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[221] => WP_Post Object
(
[ID] => 3127
[post_author] => 6
[post_date] => 2021-06-03 15:08:41
[post_date_gmt] => 2021-06-03 15:08:41
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:47:06
[post_modified_gmt] => 2022-09-27 09:47:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[222] => WP_Post Object
(
[ID] => 3126
[post_author] => 6
[post_date] => 2021-06-03 15:05:40
[post_date_gmt] => 2021-06-03 15:05:40
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:49
[post_modified_gmt] => 2021-08-23 09:52:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[223] => WP_Post Object
(
[ID] => 3125
[post_author] => 6
[post_date] => 2021-06-03 15:03:17
[post_date_gmt] => 2021-06-03 15:03:17
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:13:17
[post_modified_gmt] => 2022-03-09 13:13:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3125
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[224] => WP_Post Object
(
[ID] => 3124
[post_author] => 6
[post_date] => 2021-06-03 15:01:23
[post_date_gmt] => 2021-06-03 15:01:23
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:56
[post_modified_gmt] => 2021-08-23 09:52:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3124
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[225] => WP_Post Object
(
[ID] => 3123
[post_author] => 6
[post_date] => 2021-06-03 14:51:22
[post_date_gmt] => 2021-06-03 14:51:22
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:02:53
[post_modified_gmt] => 2022-09-29 11:02:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[226] => WP_Post Object
(
[ID] => 3122
[post_author] => 6
[post_date] => 2021-06-03 14:45:44
[post_date_gmt] => 2021-06-03 14:45:44
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:08:08
[post_modified_gmt] => 2021-11-23 15:08:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[227] => WP_Post Object
(
[ID] => 3121
[post_author] => 6
[post_date] => 2021-06-03 14:26:32
[post_date_gmt] => 2021-06-03 14:26:32
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:08
[post_modified_gmt] => 2021-08-23 09:53:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[228] => WP_Post Object
(
[ID] => 3120
[post_author] => 6
[post_date] => 2021-06-03 14:24:03
[post_date_gmt] => 2021-06-03 14:24:03
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:53:12
[post_modified_gmt] => 2021-08-23 09:53:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[229] => WP_Post Object
(
[ID] => 3119
[post_author] => 6
[post_date] => 2021-06-03 14:21:50
[post_date_gmt] => 2021-06-03 14:21:50
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 11:05:12
[post_modified_gmt] => 2022-07-13 11:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[230] => WP_Post Object
(
[ID] => 2956
[post_author] => 6
[post_date] => 2021-05-28 18:56:15
[post_date_gmt] => 2021-05-28 18:56:15
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:06
[post_modified_gmt] => 2021-08-23 10:02:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2956
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[231] => WP_Post Object
(
[ID] => 2961
[post_author] => 6
[post_date] => 2021-05-28 18:55:47
[post_date_gmt] => 2021-05-28 18:55:47
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:41:04
[post_modified_gmt] => 2021-11-23 12:41:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2961
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[232] => WP_Post Object
(
[ID] => 2965
[post_author] => 6
[post_date] => 2021-05-28 18:55:12
[post_date_gmt] => 2021-05-28 18:55:12
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:15
[post_modified_gmt] => 2021-08-23 10:02:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2965
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[233] => WP_Post Object
(
[ID] => 2947
[post_author] => 6
[post_date] => 2021-05-28 18:54:17
[post_date_gmt] => 2021-05-28 18:54:17
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:17
[post_modified_gmt] => 2021-08-23 10:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2947
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[234] => WP_Post Object
(
[ID] => 2960
[post_author] => 6
[post_date] => 2021-05-28 18:53:36
[post_date_gmt] => 2021-05-28 18:53:36
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:20
[post_modified_gmt] => 2021-08-23 10:02:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2960
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[235] => WP_Post Object
(
[ID] => 2964
[post_author] => 6
[post_date] => 2021-05-28 18:53:11
[post_date_gmt] => 2021-05-28 18:53:11
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:02:24
[post_modified_gmt] => 2021-08-23 10:02:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2964
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[236] => WP_Post Object
(
[ID] => 2958
[post_author] => 6
[post_date] => 2021-05-28 18:52:54
[post_date_gmt] => 2021-05-28 18:52:54
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 10:13:48
[post_modified_gmt] => 2021-12-03 10:13:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2958
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[237] => WP_Post Object
(
[ID] => 2949
[post_author] => 6
[post_date] => 2021-05-28 18:52:06
[post_date_gmt] => 2021-05-28 18:52:06
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:37:55
[post_modified_gmt] => 2021-11-23 12:37:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2949
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[238] => WP_Post Object
(
[ID] => 2957
[post_author] => 6
[post_date] => 2021-05-28 18:51:39
[post_date_gmt] => 2021-05-28 18:51:39
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 09:29:34
[post_modified_gmt] => 2022-09-29 09:29:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2957
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[239] => WP_Post Object
(
[ID] => 2962
[post_author] => 6
[post_date] => 2021-05-28 18:50:18
[post_date_gmt] => 2021-05-28 18:50:18
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 12:38:17
[post_modified_gmt] => 2021-11-23 12:38:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2962
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[240] => WP_Post Object
(
[ID] => 2945
[post_author] => 6
[post_date] => 2021-05-28 14:03:27
[post_date_gmt] => 2021-05-28 14:03:27
[post_content] =>
[post_title] => UK Secretary of State – AstraZeneca, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-uk-ltd-uk-secretary-of-state-for-business-energy-industrial-strategy-supply-agreement-for-azd1222
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:09:43
[post_modified_gmt] => 2022-07-13 09:09:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2945
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[241] => WP_Post Object
(
[ID] => 2909
[post_author] => 6
[post_date] => 2021-05-19 15:13:58
[post_date_gmt] => 2021-05-19 15:13:58
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 08:40:22
[post_modified_gmt] => 2022-09-26 08:40:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[242] => WP_Post Object
(
[ID] => 2908
[post_author] => 6
[post_date] => 2021-05-19 15:08:05
[post_date_gmt] => 2021-05-19 15:08:05
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:51:21
[post_modified_gmt] => 2022-09-29 10:51:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[243] => WP_Post Object
(
[ID] => 2907
[post_author] => 6
[post_date] => 2021-05-19 14:46:20
[post_date_gmt] => 2021-05-19 14:46:20
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 15:03:09
[post_modified_gmt] => 2022-08-12 15:03:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2907
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[244] => WP_Post Object
(
[ID] => 2893
[post_author] => 6
[post_date] => 2021-05-19 14:40:45
[post_date_gmt] => 2021-05-19 14:40:45
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-22 14:39:17
[post_modified_gmt] => 2022-08-22 14:39:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2893
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[245] => WP_Post Object
(
[ID] => 2892
[post_author] => 6
[post_date] => 2021-05-14 19:30:23
[post_date_gmt] => 2021-05-14 19:30:23
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-25 13:01:10
[post_modified_gmt] => 2022-08-25 13:01:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[246] => WP_Post Object
(
[ID] => 2890
[post_author] => 6
[post_date] => 2021-05-14 19:14:07
[post_date_gmt] => 2021-05-14 19:14:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-16 07:32:59
[post_modified_gmt] => 2022-09-16 07:32:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2890
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[247] => WP_Post Object
(
[ID] => 2889
[post_author] => 6
[post_date] => 2021-05-14 19:09:07
[post_date_gmt] => 2021-05-14 19:09:07
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 15:05:13
[post_modified_gmt] => 2022-08-12 15:05:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2889
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[248] => WP_Post Object
(
[ID] => 2885
[post_author] => 5
[post_date] => 2021-05-14 18:17:37
[post_date_gmt] => 2021-05-14 18:17:37
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:49:07
[post_modified_gmt] => 2022-07-13 10:49:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2885
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[249] => WP_Post Object
(
[ID] => 2824
[post_author] => 5
[post_date] => 2021-04-16 16:39:49
[post_date_gmt] => 2021-04-16 16:39:49
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:32:00
[post_modified_gmt] => 2022-09-29 12:32:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2824
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[250] => WP_Post Object
(
[ID] => 2823
[post_author] => 5
[post_date] => 2021-04-16 16:17:11
[post_date_gmt] => 2021-04-16 16:17:11
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:36:43
[post_modified_gmt] => 2022-01-18 12:36:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2823
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[251] => WP_Post Object
(
[ID] => 2822
[post_author] => 5
[post_date] => 2021-04-16 16:09:31
[post_date_gmt] => 2021-04-16 16:09:31
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-18 12:48:13
[post_modified_gmt] => 2022-01-18 12:48:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2822
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[252] => WP_Post Object
(
[ID] => 2820
[post_author] => 5
[post_date] => 2021-04-16 12:44:14
[post_date_gmt] => 2021-04-16 12:44:14
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => regeneron-ati-agreement-for-large-scale-manufacturing-of-antibodies-directed-to-sars-cov-2-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:51:41
[post_modified_gmt] => 2022-09-27 09:51:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2820
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[253] => WP_Post Object
(
[ID] => 2744
[post_author] => 5
[post_date] => 2021-03-30 15:12:35
[post_date_gmt] => 2021-03-30 15:12:35
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:48:08
[post_modified_gmt] => 2021-08-12 13:48:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2744
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[254] => WP_Post Object
(
[ID] => 2749
[post_author] => 5
[post_date] => 2021-03-30 15:10:16
[post_date_gmt] => 2021-03-30 15:10:16
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:54:16
[post_modified_gmt] => 2021-08-12 13:54:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2749
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[255] => WP_Post Object
(
[ID] => 2748
[post_author] => 5
[post_date] => 2021-03-30 15:05:46
[post_date_gmt] => 2021-03-30 15:05:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2748
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 13:52:39
[post_modified_gmt] => 2021-08-12 13:52:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2748
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[256] => WP_Post Object
(
[ID] => 2743
[post_author] => 5
[post_date] => 2021-03-24 15:11:40
[post_date_gmt] => 2021-03-24 15:11:40
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:36:08
[post_modified_gmt] => 2022-09-29 12:36:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2743
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[257] => WP_Post Object
(
[ID] => 2742
[post_author] => 5
[post_date] => 2021-03-24 13:37:07
[post_date_gmt] => 2021-03-24 13:37:07
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:28:13
[post_modified_gmt] => 2021-08-12 12:28:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2742
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[258] => WP_Post Object
(
[ID] => 2741
[post_author] => 5
[post_date] => 2021-03-24 13:32:55
[post_date_gmt] => 2021-03-24 13:32:55
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:06:52
[post_modified_gmt] => 2021-11-23 15:06:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[259] => WP_Post Object
(
[ID] => 2739
[post_author] => 5
[post_date] => 2021-03-24 13:12:14
[post_date_gmt] => 2021-03-24 13:12:14
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:47:55
[post_modified_gmt] => 2022-03-28 10:47:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2739
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[260] => WP_Post Object
(
[ID] => 2737
[post_author] => 5
[post_date] => 2021-03-24 13:00:46
[post_date_gmt] => 2021-03-24 13:00:46
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-12 12:45:35
[post_modified_gmt] => 2021-08-12 12:45:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2737
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[261] => WP_Post Object
(
[ID] => 2736
[post_author] => 5
[post_date] => 2021-03-23 18:15:15
[post_date_gmt] => 2021-03-23 18:15:15
[post_content] =>
[post_title] => US Department of Defense - Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:40:09
[post_modified_gmt] => 2022-09-27 09:40:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2736
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[262] => WP_Post Object
(
[ID] => 2734
[post_author] => 5
[post_date] => 2021-03-23 18:01:22
[post_date_gmt] => 2021-03-23 18:01:22
[post_content] =>
[post_title] => US Department of Defense – Novavax, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-us-army-agreement-for-research-development-of-covid-19-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-31 10:53:46
[post_modified_gmt] => 2022-08-31 10:53:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2734
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[263] => WP_Post Object
(
[ID] => 2543
[post_author] => 5
[post_date] => 2021-03-12 18:15:58
[post_date_gmt] => 2021-03-12 18:15:58
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 18:43:53
[post_modified_gmt] => 2022-01-04 18:43:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2543
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[264] => WP_Post Object
(
[ID] => 2540
[post_author] => 5
[post_date] => 2021-03-12 18:12:48
[post_date_gmt] => 2021-03-12 18:12:48
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 09:35:45
[post_modified_gmt] => 2022-01-05 09:35:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2540
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[265] => WP_Post Object
(
[ID] => 2541
[post_author] => 5
[post_date] => 2021-03-12 18:11:14
[post_date_gmt] => 2021-03-12 18:11:14
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:29:07
[post_modified_gmt] => 2022-09-26 14:29:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2541
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[266] => WP_Post Object
(
[ID] => 2542
[post_author] => 5
[post_date] => 2021-03-12 14:21:07
[post_date_gmt] => 2021-03-12 14:21:07
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:17:48
[post_modified_gmt] => 2022-01-05 10:17:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2542
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[267] => WP_Post Object
(
[ID] => 2544
[post_author] => 5
[post_date] => 2021-03-12 14:16:06
[post_date_gmt] => 2021-03-12 14:16:06
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 08:55:11
[post_modified_gmt] => 2022-07-13 08:55:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2544
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[268] => WP_Post Object
(
[ID] => 2545
[post_author] => 5
[post_date] => 2021-03-12 14:14:38
[post_date_gmt] => 2021-03-12 14:14:38
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:14:28
[post_modified_gmt] => 2022-03-09 13:14:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2545
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[269] => WP_Post Object
(
[ID] => 2547
[post_author] => 5
[post_date] => 2021-03-12 13:58:55
[post_date_gmt] => 2021-03-12 13:58:55
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:23:24
[post_modified_gmt] => 2022-09-29 11:23:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2547
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[270] => WP_Post Object
(
[ID] => 2549
[post_author] => 5
[post_date] => 2021-03-12 13:50:41
[post_date_gmt] => 2021-03-12 13:50:41
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 08:48:43
[post_modified_gmt] => 2022-01-05 08:48:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2549
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[271] => WP_Post Object
(
[ID] => 2553
[post_author] => 5
[post_date] => 2021-03-12 13:47:42
[post_date_gmt] => 2021-03-12 13:47:42
[post_content] =>
[post_title] => European Commission - AstraZeneca, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => astrazeneca-ec-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-05 10:59:58
[post_modified_gmt] => 2022-01-05 10:59:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2553
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[272] => WP_Post Object
(
[ID] => 2457
[post_author] => 5
[post_date] => 2021-02-25 15:25:57
[post_date_gmt] => 2021-02-25 15:25:57
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 12:14:51
[post_modified_gmt] => 2021-09-03 12:14:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2457
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[273] => WP_Post Object
(
[ID] => 2461
[post_author] => 5
[post_date] => 2021-02-25 15:23:35
[post_date_gmt] => 2021-02-25 15:23:35
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:19:55
[post_modified_gmt] => 2021-08-24 08:19:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2461
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[274] => WP_Post Object
(
[ID] => 2462
[post_author] => 5
[post_date] => 2021-02-25 15:23:19
[post_date_gmt] => 2021-02-25 15:23:19
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-30 07:11:51
[post_modified_gmt] => 2022-06-30 07:11:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2462
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[275] => WP_Post Object
(
[ID] => 2463
[post_author] => 5
[post_date] => 2021-02-25 15:22:52
[post_date_gmt] => 2021-02-25 15:22:52
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-03 13:35:23
[post_modified_gmt] => 2021-09-03 13:35:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2463
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[276] => WP_Post Object
(
[ID] => 2464
[post_author] => 5
[post_date] => 2021-02-25 15:21:51
[post_date_gmt] => 2021-02-25 15:21:51
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 15:13:03
[post_modified_gmt] => 2021-11-23 15:13:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2464
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[277] => WP_Post Object
(
[ID] => 2465
[post_author] => 5
[post_date] => 2021-02-25 15:21:32
[post_date_gmt] => 2021-02-25 15:21:32
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:37:58
[post_modified_gmt] => 2022-09-29 12:37:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2465
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[278] => WP_Post Object
(
[ID] => 2466
[post_author] => 5
[post_date] => 2021-02-25 15:20:40
[post_date_gmt] => 2021-02-25 15:20:40
[post_content] =>
[post_title] => US Department of Defense - Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:50:01
[post_modified_gmt] => 2022-03-28 10:50:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2466
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[279] => WP_Post Object
(
[ID] => 2467
[post_author] => 5
[post_date] => 2021-02-25 15:20:15
[post_date_gmt] => 2021-02-25 15:20:15
[post_content] =>
[post_title] => US Department of Defense – Sanofi, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-dod-agreement-for-adjuvanted-recombinant-covid-19-vaccine-development
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:15:33
[post_modified_gmt] => 2022-03-09 13:15:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2467
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[280] => WP_Post Object
(
[ID] => 2470
[post_author] => 5
[post_date] => 2021-01-25 13:24:13
[post_date_gmt] => 2021-01-25 13:24:13
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 13:54:22
[post_modified_gmt] => 2022-03-28 13:54:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2470
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[281] => WP_Post Object
(
[ID] => 2473
[post_author] => 5
[post_date] => 2021-01-25 13:21:58
[post_date_gmt] => 2021-01-25 13:21:58
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:14:59
[post_modified_gmt] => 2022-01-04 14:14:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2473
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[282] => WP_Post Object
(
[ID] => 2474
[post_author] => 5
[post_date] => 2021-01-25 13:19:34
[post_date_gmt] => 2021-01-25 13:19:34
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 12:54:44
[post_modified_gmt] => 2022-01-04 12:54:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2474
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[283] => WP_Post Object
(
[ID] => 2475
[post_author] => 5
[post_date] => 2021-01-25 13:18:53
[post_date_gmt] => 2021-01-25 13:18:53
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 11:57:00
[post_modified_gmt] => 2022-01-04 11:57:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2475
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[284] => WP_Post Object
(
[ID] => 2476
[post_author] => 5
[post_date] => 2021-01-25 13:18:09
[post_date_gmt] => 2021-01-25 13:18:09
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 08:54:45
[post_modified_gmt] => 2022-07-13 08:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2476
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[285] => WP_Post Object
(
[ID] => 2477
[post_author] => 5
[post_date] => 2021-01-25 13:16:23
[post_date_gmt] => 2021-01-25 13:16:23
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:38:40
[post_modified_gmt] => 2022-03-08 13:38:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2477
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[286] => WP_Post Object
(
[ID] => 2479
[post_author] => 5
[post_date] => 2021-01-25 13:12:32
[post_date_gmt] => 2021-01-25 13:12:32
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:24:51
[post_modified_gmt] => 2022-09-29 11:24:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2479
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[287] => WP_Post Object
(
[ID] => 2481
[post_author] => 5
[post_date] => 2021-01-25 13:11:08
[post_date_gmt] => 2021-01-25 13:11:08
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-19 10:39:14
[post_modified_gmt] => 2022-01-19 10:39:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2481
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[288] => WP_Post Object
(
[ID] => 2482
[post_author] => 5
[post_date] => 2021-01-25 13:09:37
[post_date_gmt] => 2021-01-25 13:09:37
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:23:50
[post_modified_gmt] => 2022-01-04 14:23:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2482
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[289] => WP_Post Object
(
[ID] => 2471
[post_author] => 5
[post_date] => 2021-01-25 13:08:02
[post_date_gmt] => 2021-01-25 13:08:02
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-ec-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 13:51:57
[post_modified_gmt] => 2022-01-04 13:51:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2471
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[290] => WP_Post Object
(
[ID] => 2452
[post_author] => 5
[post_date] => 2021-01-19 11:41:19
[post_date_gmt] => 2021-01-19 11:41:19
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-30 09:14:22
[post_modified_gmt] => 2022-06-30 09:14:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2452
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[291] => WP_Post Object
(
[ID] => 2450
[post_author] => 5
[post_date] => 2021-01-19 11:04:23
[post_date_gmt] => 2021-01-19 11:04:23
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:35:11
[post_modified_gmt] => 2022-09-29 12:35:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2450
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[292] => WP_Post Object
(
[ID] => 2449
[post_author] => 5
[post_date] => 2021-01-19 10:47:27
[post_date_gmt] => 2021-01-19 10:47:27
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:29:46
[post_modified_gmt] => 2021-11-23 14:29:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2449
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[293] => WP_Post Object
(
[ID] => 2448
[post_author] => 5
[post_date] => 2021-01-19 10:24:45
[post_date_gmt] => 2021-01-19 10:24:45
[post_content] =>
[post_title] => US Department of Defense - Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-dod-supply-agreement-for-mrna-vaccine
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:29:52
[post_modified_gmt] => 2021-11-23 14:29:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2448
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[294] => WP_Post Object
(
[ID] => 2444
[post_author] => 5
[post_date] => 2021-01-19 09:27:20
[post_date_gmt] => 2021-01-19 09:27:20
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-08 13:42:37
[post_modified_gmt] => 2022-03-08 13:42:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2444
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[295] => WP_Post Object
(
[ID] => 2443
[post_author] => 5
[post_date] => 2021-01-19 09:14:03
[post_date_gmt] => 2021-01-19 09:14:03
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:17:16
[post_modified_gmt] => 2021-11-23 14:17:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2443
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[296] => WP_Post Object
(
[ID] => 2442
[post_author] => 5
[post_date] => 2021-01-19 06:56:32
[post_date_gmt] => 2021-01-19 06:56:32
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:07:41
[post_modified_gmt] => 2022-07-13 10:07:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2442
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[297] => WP_Post Object
(
[ID] => 2441
[post_author] => 5
[post_date] => 2021-01-19 06:48:04
[post_date_gmt] => 2021-01-19 06:48:04
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-barda-contract-for-development-of-mrna-vaccine-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:40:30
[post_modified_gmt] => 2022-09-29 12:40:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2441
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[298] => WP_Post Object
(
[ID] => 2426
[post_author] => 5
[post_date] => 2020-12-14 15:02:08
[post_date_gmt] => 2020-12-14 15:02:08
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-23 13:45:05
[post_modified_gmt] => 2022-07-23 13:45:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[299] => WP_Post Object
(
[ID] => 2424
[post_author] => 5
[post_date] => 2020-12-14 15:01:40
[post_date_gmt] => 2020-12-14 15:01:40
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-collaboration-and-license-agreement-as-amended-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:21:44
[post_modified_gmt] => 2022-07-13 09:21:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[300] => WP_Post Object
(
[ID] => 3909
[post_author] => 5
[post_date] => 2021-11-22 13:29:28
[post_date_gmt] => 2021-11-22 13:29:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:13:09
[post_modified_gmt] => 2022-03-09 11:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[301] => WP_Post Object
(
[ID] => 3908
[post_author] => 5
[post_date] => 2021-11-22 13:20:09
[post_date_gmt] => 2021-11-22 13:20:09
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:04:49
[post_modified_gmt] => 2022-09-27 09:04:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[302] => WP_Post Object
(
[ID] => 3906
[post_author] => 5
[post_date] => 2021-11-22 12:57:50
[post_date_gmt] => 2021-11-22 12:57:50
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:22:44
[post_modified_gmt] => 2022-01-31 15:22:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[303] => WP_Post Object
(
[ID] => 3904
[post_author] => 5
[post_date] => 2021-11-22 12:20:20
[post_date_gmt] => 2021-11-22 12:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:00
[post_modified_gmt] => 2022-01-31 15:23:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3904
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[304] => WP_Post Object
(
[ID] => 3903
[post_author] => 5
[post_date] => 2021-11-22 12:04:07
[post_date_gmt] => 2021-11-22 12:04:07
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:16
[post_modified_gmt] => 2022-01-31 15:23:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3903
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[305] => WP_Post Object
(
[ID] => 3901
[post_author] => 5
[post_date] => 2021-11-22 11:42:55
[post_date_gmt] => 2021-11-22 11:42:55
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:34
[post_modified_gmt] => 2022-01-31 15:23:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3901
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[306] => WP_Post Object
(
[ID] => 3900
[post_author] => 5
[post_date] => 2021-11-22 11:35:10
[post_date_gmt] => 2021-11-22 11:35:10
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:08:03
[post_modified_gmt] => 2022-09-29 12:08:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3900
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[307] => WP_Post Object
(
[ID] => 3899
[post_author] => 5
[post_date] => 2021-11-22 11:24:36
[post_date_gmt] => 2021-11-22 11:24:36
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:42:51
[post_modified_gmt] => 2022-03-21 13:42:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3899
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[308] => WP_Post Object
(
[ID] => 3898
[post_author] => 5
[post_date] => 2021-11-22 11:02:44
[post_date_gmt] => 2021-11-22 11:02:44
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:24:53
[post_modified_gmt] => 2022-01-31 15:24:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3898
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[309] => WP_Post Object
(
[ID] => 3897
[post_author] => 5
[post_date] => 2021-11-22 10:34:34
[post_date_gmt] => 2021-11-22 10:34:34
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:11
[post_modified_gmt] => 2022-01-31 15:25:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3897
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[310] => WP_Post Object
(
[ID] => 3896
[post_author] => 5
[post_date] => 2021-11-22 10:27:28
[post_date_gmt] => 2021-11-22 10:27:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:40
[post_modified_gmt] => 2022-01-31 15:25:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3896
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[311] => WP_Post Object
(
[ID] => 3895
[post_author] => 5
[post_date] => 2021-11-22 10:20:20
[post_date_gmt] => 2021-11-22 10:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:14:20
[post_modified_gmt] => 2022-07-06 10:14:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3895
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[312] => WP_Post Object
(
[ID] => 3892
[post_author] => 5
[post_date] => 2021-11-19 13:53:26
[post_date_gmt] => 2021-11-19 13:53:26
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:35:42
[post_modified_gmt] => 2022-07-13 10:35:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[313] => WP_Post Object
(
[ID] => 3891
[post_author] => 5
[post_date] => 2021-11-19 13:11:12
[post_date_gmt] => 2021-11-19 13:11:12
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:15:12
[post_modified_gmt] => 2022-07-13 13:15:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3891
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[314] => WP_Post Object
(
[ID] => 3418
[post_author] => 5
[post_date] => 2021-06-30 19:06:19
[post_date_gmt] => 2021-06-30 19:06:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:03:49
[post_modified_gmt] => 2022-03-09 13:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3418
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[315] => WP_Post Object
(
[ID] => 3417
[post_author] => 5
[post_date] => 2021-06-30 19:04:34
[post_date_gmt] => 2021-06-30 19:04:34
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:39
[post_modified_gmt] => 2021-09-01 15:12:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3417
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[316] => WP_Post Object
(
[ID] => 3416
[post_author] => 5
[post_date] => 2021-06-30 19:02:19
[post_date_gmt] => 2021-06-30 19:02:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:57
[post_modified_gmt] => 2021-09-01 15:12:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3416
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[317] => WP_Post Object
(
[ID] => 3415
[post_author] => 5
[post_date] => 2021-06-30 19:00:20
[post_date_gmt] => 2021-06-30 19:00:20
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:21:29
[post_modified_gmt] => 2022-09-29 12:21:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3415
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[318] => WP_Post Object
(
[ID] => 3414
[post_author] => 5
[post_date] => 2021-06-30 18:54:43
[post_date_gmt] => 2021-06-30 18:54:43
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 12:29:49
[post_modified_gmt] => 2022-06-27 12:29:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3414
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[319] => WP_Post Object
(
[ID] => 3413
[post_author] => 5
[post_date] => 2021-06-30 18:52:08
[post_date_gmt] => 2021-06-30 18:52:08
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:10:41
[post_modified_gmt] => 2021-09-01 15:10:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3413
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[320] => WP_Post Object
(
[ID] => 3412
[post_author] => 5
[post_date] => 2021-06-30 18:48:13
[post_date_gmt] => 2021-06-30 18:48:13
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:27:17
[post_modified_gmt] => 2022-09-27 09:27:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3412
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[321] => WP_Post Object
(
[ID] => 3411
[post_author] => 5
[post_date] => 2021-06-30 18:39:53
[post_date_gmt] => 2021-06-30 18:39:53
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:30:27
[post_modified_gmt] => 2022-07-13 13:30:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3411
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[322] => WP_Post Object
(
[ID] => 3410
[post_author] => 5
[post_date] => 2021-06-30 18:37:02
[post_date_gmt] => 2021-06-30 18:37:02
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:09:38
[post_modified_gmt] => 2021-09-01 15:09:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3410
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[323] => WP_Post Object
(
[ID] => 3409
[post_author] => 5
[post_date] => 2021-06-30 18:34:04
[post_date_gmt] => 2021-06-30 18:34:04
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:58:15
[post_modified_gmt] => 2022-01-24 12:58:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3409
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[324] => WP_Post Object
(
[ID] => 3406
[post_author] => 5
[post_date] => 2021-06-30 18:25:58
[post_date_gmt] => 2021-06-30 18:25:58
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 12:21:15
[post_modified_gmt] => 2022-06-27 12:21:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3406
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[325] => WP_Post Object
(
[ID] => 3304
[post_author] => 6
[post_date] => 2021-06-30 09:30:56
[post_date_gmt] => 2021-06-30 09:30:56
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:21
[post_modified_gmt] => 2021-08-23 10:01:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[326] => WP_Post Object
(
[ID] => 2873
[post_author] => 6
[post_date] => 2021-05-11 15:17:08
[post_date_gmt] => 2021-05-11 15:17:08
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 15:50:47
[post_modified_gmt] => 2021-11-22 15:50:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[327] => WP_Post Object
(
[ID] => 2872
[post_author] => 6
[post_date] => 2021-05-11 15:14:24
[post_date_gmt] => 2021-05-11 15:14:24
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:53:55
[post_modified_gmt] => 2022-07-13 09:53:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2872
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[328] => WP_Post Object
(
[ID] => 2870
[post_author] => 6
[post_date] => 2021-05-11 15:07:59
[post_date_gmt] => 2021-05-11 15:07:59
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-15 09:15:21
[post_modified_gmt] => 2021-06-15 09:15:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[329] => WP_Post Object
(
[ID] => 2869
[post_author] => 6
[post_date] => 2021-05-11 14:53:04
[post_date_gmt] => 2021-05-11 14:53:04
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => israel-pfizer-real-world-epidemiological-evidence-collaboration-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-05-14 09:15:00
[post_modified_gmt] => 2021-05-14 09:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[330] => WP_Post Object
(
[ID] => 2867
[post_author] => 6
[post_date] => 2021-05-11 14:28:02
[post_date_gmt] => 2021-05-11 14:28:02
[post_content] =>
[post_title] => Israel – Pfizer Real-World Epidemiological Evidence Collaboration Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 2867
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:58:37
[post_modified_gmt] => 2022-09-26 14:58:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=2867
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
)
[post_count] => 331
[current_post] => -1
[in_the_loop] =>
[post] => WP_Post Object
(
[ID] => 5782
[post_author] => 5
[post_date] => 2022-09-16 07:28:56
[post_date_gmt] => 2022-09-16 07:28:56
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 08:33:07
[post_modified_gmt] => 2022-09-26 08:33:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[comment_count] => 0
[current_comment] => -1
[found_posts] => 331
[max_num_pages] => 0
[max_num_comment_pages] => 0
[is_single] =>
[is_preview] =>
[is_page] =>
[is_archive] => 1
[is_date] =>
[is_year] =>
[is_month] =>
[is_day] =>
[is_time] =>
[is_author] =>
[is_category] =>
[is_tag] =>
[is_tax] =>
[is_search] => 1
[is_feed] =>
[is_comment_feed] =>
[is_trackback] =>
[is_home] =>
[is_privacy_policy] =>
[is_404] =>
[is_embed] =>
[is_paged] =>
[is_admin] =>
[is_attachment] =>
[is_singular] =>
[is_robots] =>
[is_favicon] =>
[is_posts_page] =>
[is_post_type_archive] => 1
[query_vars_hash:WP_Query:private] => b1050dec43e5eb51fb39662feaeb2b86
[query_vars_changed:WP_Query:private] => 1
[thumbnails_cached] =>
[stopwords:WP_Query:private] => Array
(
[0] => about
[1] => an
[2] => are
[3] => as
[4] => at
[5] => be
[6] => by
[7] => com
[8] => for
[9] => from
[10] => how
[11] => in
[12] => is
[13] => it
[14] => of
[15] => on
[16] => or
[17] => that
[18] => the
[19] => this
[20] => to
[21] => was
[22] => what
[23] => when
[24] => where
[25] => who
[26] => will
[27] => with
[28] => www
)
[compat_fields:WP_Query:private] => Array
(
[0] => query_vars_hash
[1] => query_vars_changed
)
[compat_methods:WP_Query:private] => Array
(
[0] => init_query_flags
[1] => parse_tax_query
)
)
[provisions] => Array
(
[0] => WP_Post Object
(
[ID] => 5782
[post_author] => 5
[post_date] => 2022-09-16 07:28:56
[post_date_gmt] => 2022-09-16 07:28:56
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 08:33:07
[post_modified_gmt] => 2022-09-26 08:33:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[1] => WP_Post Object
(
[ID] => 5653
[post_author] => 5
[post_date] => 2022-08-25 12:56:30
[post_date_gmt] => 2022-08-25 12:56:30
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-25 12:56:30
[post_modified_gmt] => 2022-08-25 12:56:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5653
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[2] => WP_Post Object
(
[ID] => 5652
[post_author] => 5
[post_date] => 2022-08-25 12:26:53
[post_date_gmt] => 2022-08-25 12:26:53
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-25 12:26:53
[post_modified_gmt] => 2022-08-25 12:26:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5652
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[3] => WP_Post Object
(
[ID] => 5620
[post_author] => 5
[post_date] => 2022-08-12 12:05:12
[post_date_gmt] => 2022-08-12 12:05:12
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 12:05:12
[post_modified_gmt] => 2022-08-12 12:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5620
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[4] => WP_Post Object
(
[ID] => 5619
[post_author] => 5
[post_date] => 2022-08-12 12:02:21
[post_date_gmt] => 2022-08-12 12:02:21
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 12:02:21
[post_modified_gmt] => 2022-08-12 12:02:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5619
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[5] => WP_Post Object
(
[ID] => 5618
[post_author] => 5
[post_date] => 2022-08-12 11:52:17
[post_date_gmt] => 2022-08-12 11:52:17
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:52:17
[post_modified_gmt] => 2022-08-12 11:52:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5618
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[6] => WP_Post Object
(
[ID] => 5617
[post_author] => 5
[post_date] => 2022-08-12 11:49:46
[post_date_gmt] => 2022-08-12 11:49:46
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:49:46
[post_modified_gmt] => 2022-08-12 11:49:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5617
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[7] => WP_Post Object
(
[ID] => 5616
[post_author] => 5
[post_date] => 2022-08-12 11:45:22
[post_date_gmt] => 2022-08-12 11:45:22
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:45:22
[post_modified_gmt] => 2022-08-12 11:45:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5616
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[8] => WP_Post Object
(
[ID] => 5615
[post_author] => 5
[post_date] => 2022-08-12 11:40:08
[post_date_gmt] => 2022-08-12 11:40:08
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 11:40:08
[post_modified_gmt] => 2022-08-12 11:40:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5615
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[9] => WP_Post Object
(
[ID] => 5614
[post_author] => 5
[post_date] => 2022-08-12 11:34:41
[post_date_gmt] => 2022-08-12 11:34:41
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:28:05
[post_modified_gmt] => 2022-09-29 11:28:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5614
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[10] => WP_Post Object
(
[ID] => 5612
[post_author] => 5
[post_date] => 2022-08-12 10:14:31
[post_date_gmt] => 2022-08-12 10:14:31
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 10:48:37
[post_modified_gmt] => 2022-08-12 10:48:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5612
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[11] => WP_Post Object
(
[ID] => 5611
[post_author] => 5
[post_date] => 2022-08-12 10:05:33
[post_date_gmt] => 2022-08-12 10:05:33
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 10:05:33
[post_modified_gmt] => 2022-08-12 10:05:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5611
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[12] => WP_Post Object
(
[ID] => 5610
[post_author] => 5
[post_date] => 2022-08-12 09:31:00
[post_date_gmt] => 2022-08-12 09:31:00
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 09:31:00
[post_modified_gmt] => 2022-08-12 09:31:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5610
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[13] => WP_Post Object
(
[ID] => 5609
[post_author] => 5
[post_date] => 2022-08-12 09:24:43
[post_date_gmt] => 2022-08-12 09:24:43
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 09:24:43
[post_modified_gmt] => 2022-08-12 09:24:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5609
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[14] => WP_Post Object
(
[ID] => 5608
[post_author] => 5
[post_date] => 2022-08-12 09:09:54
[post_date_gmt] => 2022-08-12 09:09:54
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Grant Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-grant-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-23 13:54:19
[post_modified_gmt] => 2022-09-23 13:54:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5608
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[15] => WP_Post Object
(
[ID] => 5599
[post_author] => 5
[post_date] => 2022-08-11 14:17:45
[post_date_gmt] => 2022-08-11 14:17:45
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 12:29:33
[post_modified_gmt] => 2022-08-12 12:29:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5599
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[16] => WP_Post Object
(
[ID] => 5596
[post_author] => 5
[post_date] => 2022-08-11 12:52:07
[post_date_gmt] => 2022-08-11 12:52:07
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:52:07
[post_modified_gmt] => 2022-08-11 12:52:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5596
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[17] => WP_Post Object
(
[ID] => 5595
[post_author] => 5
[post_date] => 2022-08-11 12:36:15
[post_date_gmt] => 2022-08-11 12:36:15
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:36:15
[post_modified_gmt] => 2022-08-11 12:36:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5595
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[18] => WP_Post Object
(
[ID] => 5594
[post_author] => 5
[post_date] => 2022-08-11 12:13:32
[post_date_gmt] => 2022-08-11 12:13:32
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:46:35
[post_modified_gmt] => 2022-08-11 12:46:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5594
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[19] => WP_Post Object
(
[ID] => 5593
[post_author] => 5
[post_date] => 2022-08-11 11:48:52
[post_date_gmt] => 2022-08-11 11:48:52
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 12:26:53
[post_modified_gmt] => 2022-08-11 12:26:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5593
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[20] => WP_Post Object
(
[ID] => 5592
[post_author] => 5
[post_date] => 2022-08-11 11:16:19
[post_date_gmt] => 2022-08-11 11:16:19
[post_content] =>
[post_title] => Gates Foundation – Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-23 13:53:40
[post_modified_gmt] => 2022-09-23 13:53:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5592
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[21] => WP_Post Object
(
[ID] => 5591
[post_author] => 5
[post_date] => 2022-08-11 10:18:46
[post_date_gmt] => 2022-08-11 10:18:46
[post_content] =>
[post_title] => Gates Foundation - Icosavax, COVID-19 Vaccine Global Access and Price Commitments Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gates-foundation-icosavax-covid-19-vaccine-global-access-and-price-commitments-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-11 10:18:46
[post_modified_gmt] => 2022-08-11 10:18:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5591
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[22] => WP_Post Object
(
[ID] => 5429
[post_author] => 5
[post_date] => 2022-07-25 06:51:00
[post_date_gmt] => 2022-07-25 06:51:00
[post_content] =>
[post_title] => Sanofi – Translate Bio, Influenza and COVID-19 Vaccine Collaboration & License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => sanofi-translate-bio-influenza-and-covid-19-vaccine-collaboration-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-25 07:15:14
[post_modified_gmt] => 2022-07-25 07:15:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5429
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[23] => WP_Post Object
(
[ID] => 5123
[post_author] => 5
[post_date] => 2022-06-29 15:28:35
[post_date_gmt] => 2022-06-29 15:28:35
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 15:28:35
[post_modified_gmt] => 2022-06-29 15:28:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5123
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[24] => WP_Post Object
(
[ID] => 5122
[post_author] => 5
[post_date] => 2022-06-29 14:42:34
[post_date_gmt] => 2022-06-29 14:42:34
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => 5122
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-11 07:17:38
[post_modified_gmt] => 2022-07-11 07:17:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5122
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[25] => WP_Post Object
(
[ID] => 5121
[post_author] => 5
[post_date] => 2022-06-29 14:38:19
[post_date_gmt] => 2022-06-29 14:38:19
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:30:17
[post_modified_gmt] => 2022-09-27 09:30:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5121
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[26] => WP_Post Object
(
[ID] => 5120
[post_author] => 5
[post_date] => 2022-06-29 14:30:21
[post_date_gmt] => 2022-06-29 14:30:21
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:30:21
[post_modified_gmt] => 2022-06-29 14:30:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5120
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[27] => WP_Post Object
(
[ID] => 5119
[post_author] => 5
[post_date] => 2022-06-29 14:09:28
[post_date_gmt] => 2022-06-29 14:09:28
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:09:28
[post_modified_gmt] => 2022-06-29 14:09:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5119
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[28] => WP_Post Object
(
[ID] => 5118
[post_author] => 5
[post_date] => 2022-06-29 14:05:52
[post_date_gmt] => 2022-06-29 14:05:52
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:05:52
[post_modified_gmt] => 2022-06-29 14:05:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5118
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[29] => WP_Post Object
(
[ID] => 5117
[post_author] => 5
[post_date] => 2022-06-29 14:02:42
[post_date_gmt] => 2022-06-29 14:02:42
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:02:42
[post_modified_gmt] => 2022-06-29 14:02:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5117
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[30] => WP_Post Object
(
[ID] => 5116
[post_author] => 5
[post_date] => 2022-06-29 14:00:58
[post_date_gmt] => 2022-06-29 14:00:58
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 14:00:58
[post_modified_gmt] => 2022-06-29 14:00:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5116
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[31] => WP_Post Object
(
[ID] => 5115
[post_author] => 5
[post_date] => 2022-06-29 13:52:08
[post_date_gmt] => 2022-06-29 13:52:08
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 13:52:08
[post_modified_gmt] => 2022-06-29 13:52:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5115
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[32] => WP_Post Object
(
[ID] => 5114
[post_author] => 5
[post_date] => 2022-06-29 13:46:01
[post_date_gmt] => 2022-06-29 13:46:01
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-29 15:10:31
[post_modified_gmt] => 2022-06-29 15:10:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5114
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[33] => WP_Post Object
(
[ID] => 5113
[post_author] => 5
[post_date] => 2022-06-29 13:33:56
[post_date_gmt] => 2022-06-29 13:33:56
[post_content] =>
[post_title] => NIH – MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-11 08:34:58
[post_modified_gmt] => 2022-07-11 08:34:58
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5113
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[34] => WP_Post Object
(
[ID] => 5112
[post_author] => 5
[post_date] => 2022-06-29 13:04:55
[post_date_gmt] => 2022-06-29 13:04:55
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:33:12
[post_modified_gmt] => 2022-07-13 13:33:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5112
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[35] => WP_Post Object
(
[ID] => 5111
[post_author] => 5
[post_date] => 2022-06-29 12:40:35
[post_date_gmt] => 2022-06-29 12:40:35
[post_content] =>
[post_title] => NIH - MPP, COVID-19 Patent and Biological Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-mpp-covid-19-patent-and-biological-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:47:17
[post_modified_gmt] => 2022-07-13 10:47:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=5111
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[36] => WP_Post Object
(
[ID] => 4808
[post_author] => 5
[post_date] => 2022-05-24 09:09:54
[post_date_gmt] => 2022-05-24 09:09:54
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:49:36
[post_modified_gmt] => 2022-09-26 14:49:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[37] => WP_Post Object
(
[ID] => 4807
[post_author] => 5
[post_date] => 2022-05-24 09:02:55
[post_date_gmt] => 2022-05-24 09:02:55
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 09:02:55
[post_modified_gmt] => 2022-05-24 09:02:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[38] => WP_Post Object
(
[ID] => 4806
[post_author] => 5
[post_date] => 2022-05-24 08:59:08
[post_date_gmt] => 2022-05-24 08:59:08
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:08
[post_modified_gmt] => 2022-05-24 08:59:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[39] => WP_Post Object
(
[ID] => 4805
[post_author] => 5
[post_date] => 2022-05-24 08:53:12
[post_date_gmt] => 2022-05-24 08:53:12
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:59:42
[post_modified_gmt] => 2022-05-24 08:59:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[40] => WP_Post Object
(
[ID] => 4804
[post_author] => 5
[post_date] => 2022-05-24 08:40:15
[post_date_gmt] => 2022-05-24 08:40:15
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:53:51
[post_modified_gmt] => 2022-05-24 08:53:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[41] => WP_Post Object
(
[ID] => 4802
[post_author] => 5
[post_date] => 2022-05-24 08:24:23
[post_date_gmt] => 2022-05-24 08:24:23
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:24:23
[post_modified_gmt] => 2022-05-24 08:24:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[42] => WP_Post Object
(
[ID] => 4801
[post_author] => 5
[post_date] => 2022-05-24 08:19:21
[post_date_gmt] => 2022-05-24 08:19:21
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:19:21
[post_modified_gmt] => 2022-05-24 08:19:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[43] => WP_Post Object
(
[ID] => 4800
[post_author] => 5
[post_date] => 2022-05-24 08:07:39
[post_date_gmt] => 2022-05-24 08:07:39
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-24 08:08:30
[post_modified_gmt] => 2022-05-24 08:08:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[44] => WP_Post Object
(
[ID] => 4798
[post_author] => 5
[post_date] => 2022-05-23 14:11:13
[post_date_gmt] => 2022-05-23 14:11:13
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-23 14:12:44
[post_modified_gmt] => 2022-05-23 14:12:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[45] => WP_Post Object
(
[ID] => 4797
[post_author] => 5
[post_date] => 2022-05-23 13:54:57
[post_date_gmt] => 2022-05-23 13:54:57
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:28:31
[post_modified_gmt] => 2022-07-13 12:28:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[46] => WP_Post Object
(
[ID] => 4796
[post_author] => 5
[post_date] => 2022-05-23 13:54:05
[post_date_gmt] => 2022-05-23 13:54:05
[post_content] =>
[post_title] => CSIC-MPP, COVID-19 Antibody Diagnostic, Patent & Material License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => csic-mpp-covid-19-antibody-diagnostic-patent-material-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-17 13:44:36
[post_modified_gmt] => 2022-06-17 13:44:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[47] => WP_Post Object
(
[ID] => 4661
[post_author] => 5
[post_date] => 2022-04-20 08:13:06
[post_date_gmt] => 2022-04-20 08:13:06
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:31:12
[post_modified_gmt] => 2022-09-27 09:31:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4661
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[48] => WP_Post Object
(
[ID] => 4147
[post_author] => 5
[post_date] => 2022-04-18 12:53:51
[post_date_gmt] => 2022-04-18 12:53:51
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:22:54
[post_modified_gmt] => 2022-04-18 13:22:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4147
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[49] => WP_Post Object
(
[ID] => 4601
[post_author] => 5
[post_date] => 2022-04-18 10:40:48
[post_date_gmt] => 2022-04-18 10:40:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:44:46
[post_modified_gmt] => 2022-04-18 10:44:46
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4601
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[50] => WP_Post Object
(
[ID] => 4148
[post_author] => 5
[post_date] => 2022-04-12 08:59:45
[post_date_gmt] => 2022-04-12 08:59:45
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:11:50
[post_modified_gmt] => 2022-07-06 10:11:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4148
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[51] => WP_Post Object
(
[ID] => 4223
[post_author] => 5
[post_date] => 2022-03-04 09:43:58
[post_date_gmt] => 2022-03-04 09:43:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 18:00:18
[post_modified_gmt] => 2022-05-31 18:00:18
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4223
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[52] => WP_Post Object
(
[ID] => 4222
[post_author] => 5
[post_date] => 2022-03-04 09:14:41
[post_date_gmt] => 2022-03-04 09:14:41
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:59:19
[post_modified_gmt] => 2022-05-31 17:59:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4222
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[53] => WP_Post Object
(
[ID] => 4221
[post_author] => 5
[post_date] => 2022-03-04 09:05:29
[post_date_gmt] => 2022-03-04 09:05:29
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:36:15
[post_modified_gmt] => 2022-09-26 14:36:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[54] => WP_Post Object
(
[ID] => 4220
[post_author] => 5
[post_date] => 2022-03-04 08:47:04
[post_date_gmt] => 2022-03-04 08:47:04
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:08:10
[post_modified_gmt] => 2022-05-31 15:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[55] => WP_Post Object
(
[ID] => 4219
[post_author] => 5
[post_date] => 2022-03-04 08:02:15
[post_date_gmt] => 2022-03-04 08:02:15
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:57:38
[post_modified_gmt] => 2022-05-31 17:57:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[56] => WP_Post Object
(
[ID] => 4218
[post_author] => 5
[post_date] => 2022-03-03 14:17:53
[post_date_gmt] => 2022-03-03 14:17:53
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:57:06
[post_modified_gmt] => 2022-05-31 17:57:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[57] => WP_Post Object
(
[ID] => 4217
[post_author] => 5
[post_date] => 2022-03-03 13:59:58
[post_date_gmt] => 2022-03-03 13:59:58
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:43
[post_modified_gmt] => 2022-05-31 17:56:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[58] => WP_Post Object
(
[ID] => 4216
[post_author] => 5
[post_date] => 2022-03-03 13:45:21
[post_date_gmt] => 2022-03-03 13:45:21
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:56:00
[post_modified_gmt] => 2022-05-31 17:56:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[59] => WP_Post Object
(
[ID] => 4215
[post_author] => 5
[post_date] => 2022-03-03 13:31:56
[post_date_gmt] => 2022-03-03 13:31:56
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:41:55
[post_modified_gmt] => 2022-09-29 10:41:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[60] => WP_Post Object
(
[ID] => 4214
[post_author] => 5
[post_date] => 2022-03-03 12:54:33
[post_date_gmt] => 2022-03-03 12:54:33
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-19 13:44:17
[post_modified_gmt] => 2022-07-19 13:44:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4214
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[61] => WP_Post Object
(
[ID] => 4213
[post_author] => 5
[post_date] => 2022-03-03 10:54:01
[post_date_gmt] => 2022-03-03 10:54:01
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 15:05:32
[post_modified_gmt] => 2022-05-31 15:05:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4213
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[62] => WP_Post Object
(
[ID] => 4212
[post_author] => 5
[post_date] => 2022-03-02 14:54:16
[post_date_gmt] => 2022-03-02 14:54:16
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-31 17:54:11
[post_modified_gmt] => 2022-05-31 17:54:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4212
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[63] => WP_Post Object
(
[ID] => 4210
[post_author] => 5
[post_date] => 2022-03-02 13:14:31
[post_date_gmt] => 2022-03-02 13:14:31
[post_content] =>
[post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:03:49
[post_modified_gmt] => 2022-07-13 12:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4210
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[64] => WP_Post Object
(
[ID] => 4209
[post_author] => 5
[post_date] => 2022-03-02 12:07:13
[post_date_gmt] => 2022-03-02 12:07:13
[post_content] =>
[post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:12:02
[post_modified_gmt] => 2022-07-13 09:12:02
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4209
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[65] => WP_Post Object
(
[ID] => 4205
[post_author] => 5
[post_date] => 2022-02-28 15:24:19
[post_date_gmt] => 2022-02-28 15:24:19
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 15:24:19
[post_modified_gmt] => 2022-02-28 15:24:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4205
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[66] => WP_Post Object
(
[ID] => 4204
[post_author] => 5
[post_date] => 2022-02-28 14:53:11
[post_date_gmt] => 2022-02-28 14:53:11
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-28 14:53:11
[post_modified_gmt] => 2022-02-28 14:53:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4204
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[67] => WP_Post Object
(
[ID] => 4201
[post_author] => 5
[post_date] => 2022-02-28 13:33:22
[post_date_gmt] => 2022-02-28 13:33:22
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-25 12:24:19
[post_modified_gmt] => 2022-08-25 12:24:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4201
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[68] => WP_Post Object
(
[ID] => 4200
[post_author] => 5
[post_date] => 2022-02-28 13:13:29
[post_date_gmt] => 2022-02-28 13:13:29
[post_content] =>
[post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-15 14:39:30
[post_modified_gmt] => 2022-09-15 14:39:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4200
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[69] => WP_Post Object
(
[ID] => 4161
[post_author] => 5
[post_date] => 2022-02-02 13:48:58
[post_date_gmt] => 2022-02-02 13:48:58
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:17:00
[post_modified_gmt] => 2022-04-18 13:17:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4161
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[70] => WP_Post Object
(
[ID] => 4159
[post_author] => 5
[post_date] => 2022-02-02 13:10:48
[post_date_gmt] => 2022-02-02 13:10:48
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:16:05
[post_modified_gmt] => 2022-04-18 13:16:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4159
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[71] => WP_Post Object
(
[ID] => 4158
[post_author] => 5
[post_date] => 2022-02-02 13:00:08
[post_date_gmt] => 2022-02-02 13:00:08
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:15:30
[post_modified_gmt] => 2022-04-18 13:15:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4158
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[72] => WP_Post Object
(
[ID] => 4157
[post_author] => 5
[post_date] => 2022-02-02 12:54:56
[post_date_gmt] => 2022-02-02 12:54:56
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:13:37
[post_modified_gmt] => 2022-04-18 13:13:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4157
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[73] => WP_Post Object
(
[ID] => 4156
[post_author] => 5
[post_date] => 2022-02-02 12:36:42
[post_date_gmt] => 2022-02-02 12:36:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:51
[post_modified_gmt] => 2022-04-18 13:12:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4156
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[74] => WP_Post Object
(
[ID] => 4155
[post_author] => 5
[post_date] => 2022-02-02 12:19:16
[post_date_gmt] => 2022-02-02 12:19:16
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:12:26
[post_modified_gmt] => 2022-04-18 13:12:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4155
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[75] => WP_Post Object
(
[ID] => 4154
[post_author] => 5
[post_date] => 2022-02-02 12:13:41
[post_date_gmt] => 2022-02-02 12:13:41
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-02-02 12:13:41
[post_modified_gmt] => 2022-02-02 12:13:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4154
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[76] => WP_Post Object
(
[ID] => 4153
[post_author] => 5
[post_date] => 2022-02-02 12:10:13
[post_date_gmt] => 2022-02-02 12:10:13
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:28:28
[post_modified_gmt] => 2022-09-29 11:28:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4153
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[77] => WP_Post Object
(
[ID] => 4152
[post_author] => 5
[post_date] => 2022-02-02 11:51:54
[post_date_gmt] => 2022-02-02 11:51:54
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:57:07
[post_modified_gmt] => 2022-09-26 14:57:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4152
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[78] => WP_Post Object
(
[ID] => 4151
[post_author] => 5
[post_date] => 2022-02-02 11:39:24
[post_date_gmt] => 2022-02-02 11:39:24
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:35
[post_modified_gmt] => 2022-04-18 13:01:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4151
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[79] => WP_Post Object
(
[ID] => 4150
[post_author] => 5
[post_date] => 2022-02-02 10:24:30
[post_date_gmt] => 2022-02-02 10:24:30
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:01:03
[post_modified_gmt] => 2022-04-18 13:01:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4150
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[80] => WP_Post Object
(
[ID] => 4149
[post_author] => 5
[post_date] => 2022-02-02 10:15:42
[post_date_gmt] => 2022-02-02 10:15:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 13:00:34
[post_modified_gmt] => 2022-04-18 13:00:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4149
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[81] => WP_Post Object
(
[ID] => 4146
[post_author] => 5
[post_date] => 2022-02-02 07:28:42
[post_date_gmt] => 2022-02-02 07:28:42
[post_content] =>
[post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:45:36
[post_modified_gmt] => 2022-07-13 09:45:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4146
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[82] => WP_Post Object
(
[ID] => 4141
[post_author] => 5
[post_date] => 2022-01-31 14:31:23
[post_date_gmt] => 2022-01-31 14:31:23
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:33:23
[post_modified_gmt] => 2022-01-31 14:33:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4141
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[83] => WP_Post Object
(
[ID] => 4140
[post_author] => 5
[post_date] => 2022-01-31 14:22:03
[post_date_gmt] => 2022-01-31 14:22:03
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:11:05
[post_modified_gmt] => 2022-03-09 13:11:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4140
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[84] => WP_Post Object
(
[ID] => 4139
[post_author] => 5
[post_date] => 2022-01-31 14:18:32
[post_date_gmt] => 2022-01-31 14:18:32
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:48:21
[post_modified_gmt] => 2022-09-26 14:48:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4139
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[85] => WP_Post Object
(
[ID] => 4138
[post_author] => 5
[post_date] => 2022-01-31 14:09:33
[post_date_gmt] => 2022-01-31 14:09:33
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 14:09:33
[post_modified_gmt] => 2022-01-31 14:09:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4138
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[86] => WP_Post Object
(
[ID] => 4137
[post_author] => 5
[post_date] => 2022-01-31 13:53:37
[post_date_gmt] => 2022-01-31 13:53:37
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:54:45
[post_modified_gmt] => 2022-01-31 13:54:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4137
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[87] => WP_Post Object
(
[ID] => 4136
[post_author] => 5
[post_date] => 2022-01-31 13:42:47
[post_date_gmt] => 2022-01-31 13:42:47
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:42:47
[post_modified_gmt] => 2022-01-31 13:42:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4136
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[88] => WP_Post Object
(
[ID] => 4135
[post_author] => 5
[post_date] => 2022-01-31 13:25:08
[post_date_gmt] => 2022-01-31 13:25:08
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 13:25:08
[post_modified_gmt] => 2022-01-31 13:25:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4135
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[89] => WP_Post Object
(
[ID] => 4134
[post_author] => 5
[post_date] => 2022-01-31 12:56:28
[post_date_gmt] => 2022-01-31 12:56:28
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:52:57
[post_modified_gmt] => 2022-09-29 10:52:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4134
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[90] => WP_Post Object
(
[ID] => 4133
[post_author] => 5
[post_date] => 2022-01-31 12:22:56
[post_date_gmt] => 2022-01-31 12:22:56
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 12:24:36
[post_modified_gmt] => 2022-01-31 12:24:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4133
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[91] => WP_Post Object
(
[ID] => 4131
[post_author] => 5
[post_date] => 2022-01-29 16:21:19
[post_date_gmt] => 2022-01-29 16:21:19
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 16:31:13
[post_modified_gmt] => 2022-01-29 16:31:13
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4131
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[92] => WP_Post Object
(
[ID] => 4130
[post_author] => 5
[post_date] => 2022-01-29 15:34:50
[post_date_gmt] => 2022-01-29 15:34:50
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-29 15:49:57
[post_modified_gmt] => 2022-01-29 15:49:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4130
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[93] => WP_Post Object
(
[ID] => 4129
[post_author] => 5
[post_date] => 2022-01-28 14:43:06
[post_date_gmt] => 2022-01-28 14:43:06
[post_content] =>
[post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 09:58:49
[post_modified_gmt] => 2022-07-06 09:58:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4129
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[94] => WP_Post Object
(
[ID] => 4128
[post_author] => 5
[post_date] => 2022-01-28 13:38:44
[post_date_gmt] => 2022-01-28 13:38:44
[post_content] =>
[post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-dynavax-covid-19-material-reservation-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-28 13:45:11
[post_modified_gmt] => 2022-01-28 13:45:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4128
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[95] => WP_Post Object
(
[ID] => 4058
[post_author] => 5
[post_date] => 2022-01-04 14:25:52
[post_date_gmt] => 2022-01-04 14:25:52
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-04 14:25:52
[post_modified_gmt] => 2022-01-04 14:25:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4058
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[96] => WP_Post Object
(
[ID] => 4054
[post_author] => 5
[post_date] => 2022-01-03 11:45:52
[post_date_gmt] => 2022-01-03 11:45:52
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 11:46:09
[post_modified_gmt] => 2022-01-03 11:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4054
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[97] => WP_Post Object
(
[ID] => 4051
[post_author] => 5
[post_date] => 2022-01-03 11:01:41
[post_date_gmt] => 2022-01-03 11:01:41
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 10:37:08
[post_modified_gmt] => 2022-03-09 10:37:08
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4051
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[98] => WP_Post Object
(
[ID] => 4050
[post_author] => 5
[post_date] => 2022-01-03 10:49:32
[post_date_gmt] => 2022-01-03 10:49:32
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:56:55
[post_modified_gmt] => 2022-01-03 10:56:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4050
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[99] => WP_Post Object
(
[ID] => 4047
[post_author] => 5
[post_date] => 2021-12-27 17:17:36
[post_date_gmt] => 2021-12-27 17:17:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-03 10:43:10
[post_modified_gmt] => 2022-01-03 10:43:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4047
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[100] => WP_Post Object
(
[ID] => 4046
[post_author] => 5
[post_date] => 2021-12-27 17:10:47
[post_date_gmt] => 2021-12-27 17:10:47
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:10:47
[post_modified_gmt] => 2021-12-27 17:10:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4046
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[101] => WP_Post Object
(
[ID] => 4045
[post_author] => 5
[post_date] => 2021-12-27 17:07:25
[post_date_gmt] => 2021-12-27 17:07:25
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 17:07:25
[post_modified_gmt] => 2021-12-27 17:07:25
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4045
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[102] => WP_Post Object
(
[ID] => 4043
[post_author] => 5
[post_date] => 2021-12-27 16:47:54
[post_date_gmt] => 2021-12-27 16:47:54
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:47:54
[post_modified_gmt] => 2021-12-27 16:47:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4043
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[103] => WP_Post Object
(
[ID] => 4042
[post_author] => 5
[post_date] => 2021-12-27 16:41:56
[post_date_gmt] => 2021-12-27 16:41:56
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:25:56
[post_modified_gmt] => 2022-09-29 12:25:56
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4042
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[104] => WP_Post Object
(
[ID] => 4041
[post_author] => 5
[post_date] => 2021-12-27 16:28:21
[post_date_gmt] => 2021-12-27 16:28:21
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-27 16:28:42
[post_modified_gmt] => 2021-12-27 16:28:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4041
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[105] => WP_Post Object
(
[ID] => 4040
[post_author] => 5
[post_date] => 2021-12-27 15:24:04
[post_date_gmt] => 2021-12-27 15:24:04
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-14 12:58:21
[post_modified_gmt] => 2022-03-14 12:58:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4040
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[106] => WP_Post Object
(
[ID] => 4038
[post_author] => 5
[post_date] => 2021-12-27 15:08:30
[post_date_gmt] => 2021-12-27 15:08:30
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:22:28
[post_modified_gmt] => 2022-01-24 12:22:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4038
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[107] => WP_Post Object
(
[ID] => 4036
[post_author] => 5
[post_date] => 2021-12-26 17:01:45
[post_date_gmt] => 2021-12-26 17:01:45
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:46:09
[post_modified_gmt] => 2022-09-27 09:46:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4036
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[108] => WP_Post Object
(
[ID] => 4035
[post_author] => 5
[post_date] => 2021-12-26 16:47:36
[post_date_gmt] => 2021-12-26 16:47:36
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-26 16:47:36
[post_modified_gmt] => 2021-12-26 16:47:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4035
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[109] => WP_Post Object
(
[ID] => 4032
[post_author] => 5
[post_date] => 2021-12-26 16:32:27
[post_date_gmt] => 2021-12-26 16:32:27
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-22 14:37:29
[post_modified_gmt] => 2022-01-22 14:37:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4032
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[110] => WP_Post Object
(
[ID] => 4029
[post_author] => 5
[post_date] => 2021-12-21 12:22:08
[post_date_gmt] => 2021-12-21 12:22:08
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 14:31:07
[post_modified_gmt] => 2022-06-27 14:31:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4029
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[111] => WP_Post Object
(
[ID] => 4028
[post_author] => 5
[post_date] => 2021-12-21 11:55:28
[post_date_gmt] => 2021-12-21 11:55:28
[post_content] =>
[post_title] => Ocugen-BBIL, COVID-19 Vaccine (Covaxin), Co-development, Supply & Commercialization Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ocugen-bbil-covid-19-vaccine-covaxin-co-development-supply-commercialization-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 11:03:21
[post_modified_gmt] => 2022-07-13 11:03:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4028
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[112] => WP_Post Object
(
[ID] => 4024
[post_author] => 5
[post_date] => 2021-12-15 15:33:17
[post_date_gmt] => 2021-12-15 15:33:17
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-22
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 15:33:17
[post_modified_gmt] => 2021-12-15 15:33:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4024
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[113] => WP_Post Object
(
[ID] => 4022
[post_author] => 5
[post_date] => 2021-12-15 14:49:36
[post_date_gmt] => 2021-12-15 14:49:36
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-20
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:51:23
[post_modified_gmt] => 2021-12-15 14:51:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4022
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[114] => WP_Post Object
(
[ID] => 4021
[post_author] => 5
[post_date] => 2021-12-15 14:31:00
[post_date_gmt] => 2021-12-15 14:31:00
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:31:00
[post_modified_gmt] => 2021-12-15 14:31:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4021
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[115] => WP_Post Object
(
[ID] => 4020
[post_author] => 5
[post_date] => 2021-12-15 14:24:47
[post_date_gmt] => 2021-12-15 14:24:47
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-18
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 14:24:47
[post_modified_gmt] => 2021-12-15 14:24:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4020
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[116] => WP_Post Object
(
[ID] => 4017
[post_author] => 5
[post_date] => 2021-12-15 13:22:49
[post_date_gmt] => 2021-12-15 13:22:49
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 13:22:49
[post_modified_gmt] => 2021-12-15 13:22:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4017
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[117] => WP_Post Object
(
[ID] => 4016
[post_author] => 5
[post_date] => 2021-12-15 13:20:07
[post_date_gmt] => 2021-12-15 13:20:07
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 10:54:29
[post_modified_gmt] => 2022-09-29 10:54:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4016
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[118] => WP_Post Object
(
[ID] => 4014
[post_author] => 5
[post_date] => 2021-12-15 12:33:09
[post_date_gmt] => 2021-12-15 12:33:09
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:33:09
[post_modified_gmt] => 2021-12-15 12:33:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4014
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[119] => WP_Post Object
(
[ID] => 4013
[post_author] => 5
[post_date] => 2021-12-15 12:16:20
[post_date_gmt] => 2021-12-15 12:16:20
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-15 12:17:01
[post_modified_gmt] => 2021-12-15 12:17:01
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4013
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[120] => WP_Post Object
(
[ID] => 4011
[post_author] => 5
[post_date] => 2021-12-14 15:21:54
[post_date_gmt] => 2021-12-14 15:21:54
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:25:12
[post_modified_gmt] => 2022-07-13 09:25:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4011
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[121] => WP_Post Object
(
[ID] => 4009
[post_author] => 5
[post_date] => 2021-12-14 15:10:51
[post_date_gmt] => 2021-12-14 15:10:51
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:00:07
[post_modified_gmt] => 2022-03-09 11:00:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4009
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[122] => WP_Post Object
(
[ID] => 4007
[post_author] => 5
[post_date] => 2021-12-14 08:51:32
[post_date_gmt] => 2021-12-14 08:51:32
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 08:51:44
[post_modified_gmt] => 2021-12-14 08:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4007
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[123] => WP_Post Object
(
[ID] => 4006
[post_author] => 5
[post_date] => 2021-12-14 08:16:01
[post_date_gmt] => 2021-12-14 08:16:01
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-23 14:46:11
[post_modified_gmt] => 2022-03-23 14:46:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4006
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[124] => WP_Post Object
(
[ID] => 4004
[post_author] => 5
[post_date] => 2021-12-14 07:57:41
[post_date_gmt] => 2021-12-14 07:57:41
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-14 07:57:41
[post_modified_gmt] => 2021-12-14 07:57:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4004
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[125] => WP_Post Object
(
[ID] => 4003
[post_author] => 5
[post_date] => 2021-12-13 18:36:53
[post_date_gmt] => 2021-12-13 18:36:53
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:50:30
[post_modified_gmt] => 2022-09-26 14:50:30
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4003
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[126] => WP_Post Object
(
[ID] => 4002
[post_author] => 5
[post_date] => 2021-12-13 18:28:05
[post_date_gmt] => 2021-12-13 18:28:05
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-13 18:41:28
[post_modified_gmt] => 2021-12-13 18:41:28
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=4002
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[127] => WP_Post Object
(
[ID] => 3997
[post_author] => 5
[post_date] => 2021-12-13 14:24:49
[post_date_gmt] => 2021-12-13 14:24:49
[post_content] =>
[post_title] => CureVac - GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-gsk-covid-19-vaccine-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:52:42
[post_modified_gmt] => 2022-07-13 12:52:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3997
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[128] => WP_Post Object
(
[ID] => 3909
[post_author] => 5
[post_date] => 2021-11-22 13:29:28
[post_date_gmt] => 2021-11-22 13:29:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:13:09
[post_modified_gmt] => 2022-03-09 11:13:09
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3909
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[129] => WP_Post Object
(
[ID] => 3908
[post_author] => 5
[post_date] => 2021-11-22 13:20:09
[post_date_gmt] => 2021-11-22 13:20:09
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:04:49
[post_modified_gmt] => 2022-09-27 09:04:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3908
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[130] => WP_Post Object
(
[ID] => 3906
[post_author] => 5
[post_date] => 2021-11-22 12:57:50
[post_date_gmt] => 2021-11-22 12:57:50
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:22:44
[post_modified_gmt] => 2022-01-31 15:22:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3906
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[131] => WP_Post Object
(
[ID] => 3904
[post_author] => 5
[post_date] => 2021-11-22 12:20:20
[post_date_gmt] => 2021-11-22 12:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:00
[post_modified_gmt] => 2022-01-31 15:23:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3904
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[132] => WP_Post Object
(
[ID] => 3903
[post_author] => 5
[post_date] => 2021-11-22 12:04:07
[post_date_gmt] => 2021-11-22 12:04:07
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:16
[post_modified_gmt] => 2022-01-31 15:23:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3903
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[133] => WP_Post Object
(
[ID] => 3901
[post_author] => 5
[post_date] => 2021-11-22 11:42:55
[post_date_gmt] => 2021-11-22 11:42:55
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:23:34
[post_modified_gmt] => 2022-01-31 15:23:34
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3901
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[134] => WP_Post Object
(
[ID] => 3900
[post_author] => 5
[post_date] => 2021-11-22 11:35:10
[post_date_gmt] => 2021-11-22 11:35:10
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:08:03
[post_modified_gmt] => 2022-09-29 12:08:03
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3900
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[135] => WP_Post Object
(
[ID] => 3899
[post_author] => 5
[post_date] => 2021-11-22 11:24:36
[post_date_gmt] => 2021-11-22 11:24:36
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-21 13:42:51
[post_modified_gmt] => 2022-03-21 13:42:51
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3899
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[136] => WP_Post Object
(
[ID] => 3898
[post_author] => 5
[post_date] => 2021-11-22 11:02:44
[post_date_gmt] => 2021-11-22 11:02:44
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:24:53
[post_modified_gmt] => 2022-01-31 15:24:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3898
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[137] => WP_Post Object
(
[ID] => 3897
[post_author] => 5
[post_date] => 2021-11-22 10:34:34
[post_date_gmt] => 2021-11-22 10:34:34
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:11
[post_modified_gmt] => 2022-01-31 15:25:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3897
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[138] => WP_Post Object
(
[ID] => 3896
[post_author] => 5
[post_date] => 2021-11-22 10:27:28
[post_date_gmt] => 2021-11-22 10:27:28
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-31 15:25:40
[post_modified_gmt] => 2022-01-31 15:25:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3896
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[139] => WP_Post Object
(
[ID] => 3895
[post_author] => 5
[post_date] => 2021-11-22 10:20:20
[post_date_gmt] => 2021-11-22 10:20:20
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:14:20
[post_modified_gmt] => 2022-07-06 10:14:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3895
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[140] => WP_Post Object
(
[ID] => 3892
[post_author] => 5
[post_date] => 2021-11-19 13:53:26
[post_date_gmt] => 2021-11-19 13:53:26
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:35:42
[post_modified_gmt] => 2022-07-13 10:35:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3892
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[141] => WP_Post Object
(
[ID] => 3891
[post_author] => 5
[post_date] => 2021-11-19 13:11:12
[post_date_gmt] => 2021-11-19 13:11:12
[post_content] =>
[post_title] => MSD – MPP, Molnupiravir License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => msd-mpp-molnupiravir-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:15:12
[post_modified_gmt] => 2022-07-13 13:15:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3891
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[142] => WP_Post Object
(
[ID] => 3869
[post_author] => 5
[post_date] => 2021-11-19 12:55:06
[post_date_gmt] => 2021-11-19 12:55:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:09:23
[post_modified_gmt] => 2022-07-13 10:09:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3869
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[143] => WP_Post Object
(
[ID] => 3886
[post_author] => 5
[post_date] => 2021-11-18 16:36:37
[post_date_gmt] => 2021-11-18 16:36:37
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 06:09:26
[post_modified_gmt] => 2022-04-12 06:09:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3886
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[144] => WP_Post Object
(
[ID] => 3884
[post_author] => 5
[post_date] => 2021-11-18 16:17:51
[post_date_gmt] => 2021-11-18 16:17:51
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 11:17:21
[post_modified_gmt] => 2022-03-09 11:17:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3884
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[145] => WP_Post Object
(
[ID] => 3883
[post_author] => 5
[post_date] => 2021-11-18 16:10:24
[post_date_gmt] => 2021-11-18 16:10:24
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:48:26
[post_modified_gmt] => 2021-12-03 12:48:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3883
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[146] => WP_Post Object
(
[ID] => 3882
[post_author] => 5
[post_date] => 2021-11-18 16:01:06
[post_date_gmt] => 2021-11-18 16:01:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2021-12-03 12:49:07
[post_modified_gmt] => 2021-12-03 12:49:07
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3882
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[147] => WP_Post Object
(
[ID] => 3881
[post_author] => 5
[post_date] => 2021-11-18 15:52:45
[post_date_gmt] => 2021-11-18 15:52:45
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:52:45
[post_modified_gmt] => 2021-11-18 15:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3881
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[148] => WP_Post Object
(
[ID] => 3880
[post_author] => 5
[post_date] => 2021-11-18 15:50:26
[post_date_gmt] => 2021-11-18 15:50:26
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:50:26
[post_modified_gmt] => 2021-11-18 15:50:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3880
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[149] => WP_Post Object
(
[ID] => 3878
[post_author] => 5
[post_date] => 2021-11-18 15:08:19
[post_date_gmt] => 2021-11-18 15:08:19
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 15:08:19
[post_modified_gmt] => 2021-11-18 15:08:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3878
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[150] => WP_Post Object
(
[ID] => 3877
[post_author] => 5
[post_date] => 2021-11-18 15:05:16
[post_date_gmt] => 2021-11-18 15:05:16
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:45:57
[post_modified_gmt] => 2022-09-29 11:45:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3877
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[151] => WP_Post Object
(
[ID] => 3876
[post_author] => 5
[post_date] => 2021-11-18 14:51:40
[post_date_gmt] => 2021-11-18 14:51:40
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-18 14:51:40
[post_modified_gmt] => 2021-11-18 14:51:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3876
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[152] => WP_Post Object
(
[ID] => 3875
[post_author] => 5
[post_date] => 2021-11-18 14:43:39
[post_date_gmt] => 2021-11-18 14:43:39
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-22 10:50:23
[post_modified_gmt] => 2021-11-22 10:50:23
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3875
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[153] => WP_Post Object
(
[ID] => 3874
[post_author] => 5
[post_date] => 2021-11-18 14:29:06
[post_date_gmt] => 2021-11-18 14:29:06
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-12 08:08:10
[post_modified_gmt] => 2022-04-12 08:08:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3874
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[154] => WP_Post Object
(
[ID] => 3873
[post_author] => 5
[post_date] => 2021-11-18 14:05:12
[post_date_gmt] => 2021-11-18 14:05:12
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-19 12:22:45
[post_modified_gmt] => 2021-11-19 12:22:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3873
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[155] => WP_Post Object
(
[ID] => 3870
[post_author] => 5
[post_date] => 2021-11-18 12:58:35
[post_date_gmt] => 2021-11-18 12:58:35
[post_content] =>
[post_title] => Moderna – Lonza, COVID-19 mRNA Vaccine & Therapies, Manufacturing & Process Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => moderna-lonza-covid-19-mrna-vaccine-therapies-manufacturing-process-development-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:14:06
[post_modified_gmt] => 2022-07-13 13:14:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3870
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[156] => WP_Post Object
(
[ID] => 3863
[post_author] => 5
[post_date] => 2021-11-05 14:19:38
[post_date_gmt] => 2021-11-05 14:19:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-19
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:22:42
[post_modified_gmt] => 2022-04-18 09:22:42
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3863
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[157] => WP_Post Object
(
[ID] => 3861
[post_author] => 5
[post_date] => 2021-11-05 13:59:54
[post_date_gmt] => 2021-11-05 13:59:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:26
[post_modified_gmt] => 2022-04-18 07:16:26
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3861
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[158] => WP_Post Object
(
[ID] => 3860
[post_author] => 5
[post_date] => 2021-11-05 13:51:48
[post_date_gmt] => 2021-11-05 13:51:48
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-16
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:16:48
[post_modified_gmt] => 2022-04-18 07:16:48
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3860
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[159] => WP_Post Object
(
[ID] => 3859
[post_author] => 5
[post_date] => 2021-11-05 13:44:47
[post_date_gmt] => 2021-11-05 13:44:47
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:28:57
[post_modified_gmt] => 2022-04-18 07:28:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3859
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[160] => WP_Post Object
(
[ID] => 3858
[post_author] => 5
[post_date] => 2021-11-05 13:39:37
[post_date_gmt] => 2021-11-05 13:39:37
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:54:11
[post_modified_gmt] => 2022-04-18 07:54:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3858
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[161] => WP_Post Object
(
[ID] => 3857
[post_author] => 5
[post_date] => 2021-11-05 13:37:12
[post_date_gmt] => 2021-11-05 13:37:12
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 07:41:41
[post_modified_gmt] => 2022-04-18 07:41:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3857
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[162] => WP_Post Object
(
[ID] => 3856
[post_author] => 5
[post_date] => 2021-11-05 13:12:38
[post_date_gmt] => 2021-11-05 13:12:38
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:54:20
[post_modified_gmt] => 2022-09-26 14:54:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3856
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[163] => WP_Post Object
(
[ID] => 3855
[post_author] => 5
[post_date] => 2021-11-05 13:10:25
[post_date_gmt] => 2021-11-05 13:10:25
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:08:38
[post_modified_gmt] => 2022-07-06 10:08:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3855
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[164] => WP_Post Object
(
[ID] => 3854
[post_author] => 5
[post_date] => 2021-11-05 13:03:41
[post_date_gmt] => 2021-11-05 13:03:41
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:15:00
[post_modified_gmt] => 2022-04-18 08:15:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3854
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[165] => WP_Post Object
(
[ID] => 3852
[post_author] => 5
[post_date] => 2021-11-05 12:43:57
[post_date_gmt] => 2021-11-05 12:43:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:33:20
[post_modified_gmt] => 2022-04-18 08:33:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3852
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[166] => WP_Post Object
(
[ID] => 3851
[post_author] => 5
[post_date] => 2021-11-05 12:41:54
[post_date_gmt] => 2021-11-05 12:41:54
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:45:20
[post_modified_gmt] => 2022-04-18 08:45:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3851
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[167] => WP_Post Object
(
[ID] => 3849
[post_author] => 5
[post_date] => 2021-11-05 12:30:09
[post_date_gmt] => 2021-11-05 12:30:09
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:52:12
[post_modified_gmt] => 2022-04-18 08:52:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3849
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[168] => WP_Post Object
(
[ID] => 3848
[post_author] => 5
[post_date] => 2021-11-05 12:27:44
[post_date_gmt] => 2021-11-05 12:27:44
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 08:58:14
[post_modified_gmt] => 2022-04-18 08:58:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3848
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[169] => WP_Post Object
(
[ID] => 3847
[post_author] => 5
[post_date] => 2021-11-05 12:25:40
[post_date_gmt] => 2021-11-05 12:25:40
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 09:38:24
[post_modified_gmt] => 2022-07-13 09:38:24
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3847
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[170] => WP_Post Object
(
[ID] => 3846
[post_author] => 5
[post_date] => 2021-11-05 12:14:17
[post_date_gmt] => 2021-11-05 12:14:17
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Vaccine Technology Transfer Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-vaccine-technology-transfer-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:02:17
[post_modified_gmt] => 2022-07-13 13:02:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3846
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[171] => WP_Post Object
(
[ID] => 3819
[post_author] => 6
[post_date] => 2021-09-15 12:17:55
[post_date_gmt] => 2021-09-15 12:17:55
[post_content] =>
[post_title] => CureVac – GSK, COVID-19 Vaccine Collaboration and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => curevac-and-gsk-collaboration-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 12:51:14
[post_modified_gmt] => 2022-07-13 12:51:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3819
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[172] => WP_Post Object
(
[ID] => 3812
[post_author] => 5
[post_date] => 2021-09-10 12:44:57
[post_date_gmt] => 2021-09-10 12:44:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:13:50
[post_modified_gmt] => 2022-04-20 09:13:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3812
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[173] => WP_Post Object
(
[ID] => 3810
[post_author] => 5
[post_date] => 2021-09-10 12:21:33
[post_date_gmt] => 2021-09-10 12:21:33
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:11:54
[post_modified_gmt] => 2022-04-20 07:11:54
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3810
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[174] => WP_Post Object
(
[ID] => 3809
[post_author] => 5
[post_date] => 2021-09-10 12:11:12
[post_date_gmt] => 2021-09-10 12:11:12
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 09:19:45
[post_modified_gmt] => 2022-04-20 09:19:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3809
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[175] => WP_Post Object
(
[ID] => 3808
[post_author] => 5
[post_date] => 2021-09-10 11:59:11
[post_date_gmt] => 2021-09-10 11:59:11
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:24:05
[post_modified_gmt] => 2022-04-20 07:24:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3808
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[176] => WP_Post Object
(
[ID] => 3807
[post_author] => 5
[post_date] => 2021-09-10 11:55:25
[post_date_gmt] => 2021-09-10 11:55:25
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:42:12
[post_modified_gmt] => 2022-04-20 07:42:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3807
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[177] => WP_Post Object
(
[ID] => 3806
[post_author] => 5
[post_date] => 2021-09-10 11:47:18
[post_date_gmt] => 2021-09-10 11:47:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:17:33
[post_modified_gmt] => 2022-07-06 10:17:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3806
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[178] => WP_Post Object
(
[ID] => 3805
[post_author] => 5
[post_date] => 2021-09-10 11:33:53
[post_date_gmt] => 2021-09-10 11:33:53
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:46:59
[post_modified_gmt] => 2022-04-20 07:46:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3805
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[179] => WP_Post Object
(
[ID] => 3804
[post_author] => 5
[post_date] => 2021-09-10 11:20:59
[post_date_gmt] => 2021-09-10 11:20:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:50:11
[post_modified_gmt] => 2022-04-20 07:50:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3804
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[180] => WP_Post Object
(
[ID] => 3803
[post_author] => 5
[post_date] => 2021-09-10 10:54:42
[post_date_gmt] => 2021-09-10 10:54:42
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:51:06
[post_modified_gmt] => 2022-04-20 07:51:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3803
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[181] => WP_Post Object
(
[ID] => 3802
[post_author] => 5
[post_date] => 2021-09-10 10:45:57
[post_date_gmt] => 2021-09-10 10:45:57
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 07:54:14
[post_modified_gmt] => 2022-04-20 07:54:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3802
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[182] => WP_Post Object
(
[ID] => 3801
[post_author] => 5
[post_date] => 2021-09-10 10:36:30
[post_date_gmt] => 2021-09-10 10:36:30
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:05:17
[post_modified_gmt] => 2022-04-20 08:05:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3801
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[183] => WP_Post Object
(
[ID] => 3800
[post_author] => 5
[post_date] => 2021-09-10 10:25:59
[post_date_gmt] => 2021-09-10 10:25:59
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:35:52
[post_modified_gmt] => 2022-04-20 08:35:52
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3800
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[184] => WP_Post Object
(
[ID] => 3799
[post_author] => 5
[post_date] => 2021-09-10 10:07:18
[post_date_gmt] => 2021-09-10 10:07:18
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-20 08:44:40
[post_modified_gmt] => 2022-04-20 08:44:40
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3799
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[185] => WP_Post Object
(
[ID] => 3798
[post_author] => 5
[post_date] => 2021-09-10 10:02:07
[post_date_gmt] => 2021-09-10 10:02:07
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:35:06
[post_modified_gmt] => 2022-07-13 13:35:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3798
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[186] => WP_Post Object
(
[ID] => 3797
[post_author] => 5
[post_date] => 2021-09-10 09:54:44
[post_date_gmt] => 2021-09-10 09:54:44
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 10:57:55
[post_modified_gmt] => 2022-07-13 10:57:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3797
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[187] => WP_Post Object
(
[ID] => 3796
[post_author] => 5
[post_date] => 2021-09-10 09:03:43
[post_date_gmt] => 2021-09-10 09:03:43
[post_content] =>
[post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 13:10:22
[post_modified_gmt] => 2022-06-27 13:10:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3796
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[188] => WP_Post Object
(
[ID] => 3792
[post_author] => 5
[post_date] => 2021-09-09 14:23:13
[post_date_gmt] => 2021-09-09 14:23:13
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 12:44:33
[post_modified_gmt] => 2022-03-09 12:44:33
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3792
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[189] => WP_Post Object
(
[ID] => 3791
[post_author] => 5
[post_date] => 2021-09-09 14:18:44
[post_date_gmt] => 2021-09-09 14:18:44
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:00:35
[post_modified_gmt] => 2021-11-04 09:00:35
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3791
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[190] => WP_Post Object
(
[ID] => 3789
[post_author] => 5
[post_date] => 2021-09-09 14:07:30
[post_date_gmt] => 2021-09-09 14:07:30
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:32:36
[post_modified_gmt] => 2022-09-29 12:32:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3789
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[191] => WP_Post Object
(
[ID] => 3788
[post_author] => 5
[post_date] => 2021-09-09 14:00:40
[post_date_gmt] => 2021-09-09 14:00:40
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:02:12
[post_modified_gmt] => 2021-11-04 09:02:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3788
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[192] => WP_Post Object
(
[ID] => 3786
[post_author] => 5
[post_date] => 2021-09-09 13:20:21
[post_date_gmt] => 2021-09-09 13:20:21
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:53:55
[post_modified_gmt] => 2022-05-27 08:53:55
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3786
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[193] => WP_Post Object
(
[ID] => 3785
[post_author] => 5
[post_date] => 2021-09-09 13:10:11
[post_date_gmt] => 2021-09-09 13:10:11
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:04:36
[post_modified_gmt] => 2021-11-04 09:04:36
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3785
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[194] => WP_Post Object
(
[ID] => 3784
[post_author] => 5
[post_date] => 2021-09-09 13:03:52
[post_date_gmt] => 2021-09-09 13:03:52
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:12
[post_modified_gmt] => 2021-11-04 09:05:12
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3784
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[195] => WP_Post Object
(
[ID] => 3783
[post_author] => 5
[post_date] => 2021-09-09 12:41:47
[post_date_gmt] => 2021-09-09 12:41:47
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-04 09:05:50
[post_modified_gmt] => 2021-11-04 09:05:50
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3783
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[196] => WP_Post Object
(
[ID] => 3782
[post_author] => 5
[post_date] => 2021-09-09 12:36:36
[post_date_gmt] => 2021-09-09 12:36:36
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-30 09:42:22
[post_modified_gmt] => 2022-08-30 09:42:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3782
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[197] => WP_Post Object
(
[ID] => 3781
[post_author] => 5
[post_date] => 2021-09-09 12:29:54
[post_date_gmt] => 2021-09-09 12:29:54
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-23 14:18:43
[post_modified_gmt] => 2021-11-23 14:18:43
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3781
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[198] => WP_Post Object
(
[ID] => 3778
[post_author] => 5
[post_date] => 2021-09-09 11:52:53
[post_date_gmt] => 2021-09-09 11:52:53
[post_content] =>
[post_title] => US Department of Defense - Janssen, COVID-19 Vaccine Large Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => us-department-of-defense-janssen-covid-19-vaccine-large-scale-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:59:06
[post_modified_gmt] => 2022-09-27 09:59:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3778
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[199] => WP_Post Object
(
[ID] => 3765
[post_author] => 5
[post_date] => 2021-09-01 14:09:03
[post_date_gmt] => 2021-09-01 14:09:03
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:49:00
[post_modified_gmt] => 2022-03-28 10:49:00
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3765
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[200] => WP_Post Object
(
[ID] => 3764
[post_author] => 5
[post_date] => 2021-09-01 12:17:32
[post_date_gmt] => 2021-09-01 12:17:32
[post_content] =>
[post_title] => BARDA – Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:59:16
[post_modified_gmt] => 2022-09-26 14:59:16
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3764
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[201] => WP_Post Object
(
[ID] => 3758
[post_author] => 5
[post_date] => 2021-08-26 12:04:03
[post_date_gmt] => 2021-08-26 12:04:03
[post_content] =>
[post_title] => BARDA - Moderna, COVID-19 Vaccine Development Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => barda-moderna-covid-19-vaccine-development-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:43:14
[post_modified_gmt] => 2022-03-28 10:43:14
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3758
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[202] => WP_Post Object
(
[ID] => 3741
[post_author] => 5
[post_date] => 2021-08-24 09:13:39
[post_date_gmt] => 2021-08-24 09:13:39
[post_content] =>
[post_title] => European Commission - CureVac, COVID-19 Vaccine Advance Purchase Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => european-commission-curevac-covid-19-vaccine-advance-purchase-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:25:32
[post_modified_gmt] => 2022-09-26 14:25:32
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3741
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[203] => WP_Post Object
(
[ID] => 3696
[post_author] => 5
[post_date] => 2021-08-19 14:23:22
[post_date_gmt] => 2021-08-19 14:23:22
[post_content] =>
[post_title] => US Army Contracting Command (via ATI) – Regeneron, COVID-19 Antibodies Large-Scale Manufacturing Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => ati-regeneron-covid-19-antibodies-manufacturing-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-05-27 08:46:20
[post_modified_gmt] => 2022-05-27 08:46:20
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3696
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[204] => WP_Post Object
(
[ID] => 3495
[post_author] => 5
[post_date] => 2021-08-10 13:06:45
[post_date_gmt] => 2021-08-10 13:06:45
[post_content] =>
[post_title] => US Department of Defense – Moderna, COVID-19 Vaccine Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => dod-moderna-covid-19-vaccine-supply-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2021-11-29 14:12:04
[post_modified_gmt] => 2021-11-29 14:12:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3495
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[205] => WP_Post Object
(
[ID] => 3493
[post_author] => 5
[post_date] => 2021-08-10 11:15:39
[post_date_gmt] => 2021-08-10 11:15:39
[post_content] =>
[post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-08-12 14:59:31
[post_modified_gmt] => 2022-08-12 14:59:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3493
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[206] => WP_Post Object
(
[ID] => 3436
[post_author] => 6
[post_date] => 2021-07-01 03:48:49
[post_date_gmt] => 2021-07-01 03:48:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-13
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 11:25:22
[post_modified_gmt] => 2022-09-29 11:25:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3436
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[207] => WP_Post Object
(
[ID] => 3434
[post_author] => 6
[post_date] => 2021-07-01 03:44:18
[post_date_gmt] => 2021-07-01 03:44:18
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:28:59
[post_modified_gmt] => 2022-04-18 09:28:59
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3434
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[208] => WP_Post Object
(
[ID] => 3433
[post_author] => 6
[post_date] => 2021-07-01 03:41:21
[post_date_gmt] => 2021-07-01 03:41:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:32:11
[post_modified_gmt] => 2022-04-18 09:32:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3433
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[209] => WP_Post Object
(
[ID] => 3431
[post_author] => 6
[post_date] => 2021-07-01 03:38:49
[post_date_gmt] => 2021-07-01 03:38:49
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:41:10
[post_modified_gmt] => 2022-04-18 09:41:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3431
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[210] => WP_Post Object
(
[ID] => 3430
[post_author] => 6
[post_date] => 2021-07-01 03:27:51
[post_date_gmt] => 2021-07-01 03:27:51
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:45:31
[post_modified_gmt] => 2022-04-18 09:45:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3430
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[211] => WP_Post Object
(
[ID] => 3428
[post_author] => 6
[post_date] => 2021-07-01 03:24:00
[post_date_gmt] => 2021-07-01 03:24:00
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-26 14:52:47
[post_modified_gmt] => 2022-09-26 14:52:47
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3428
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[212] => WP_Post Object
(
[ID] => 3427
[post_author] => 6
[post_date] => 2021-07-01 03:22:23
[post_date_gmt] => 2021-07-01 03:22:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 09:49:38
[post_modified_gmt] => 2022-04-18 09:49:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3427
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[213] => WP_Post Object
(
[ID] => 3426
[post_author] => 6
[post_date] => 2021-07-01 03:06:23
[post_date_gmt] => 2021-07-01 03:06:23
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:28:05
[post_modified_gmt] => 2022-04-18 10:28:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3426
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[214] => WP_Post Object
(
[ID] => 3424
[post_author] => 6
[post_date] => 2021-07-01 03:03:57
[post_date_gmt] => 2021-07-01 03:03:57
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:47:10
[post_modified_gmt] => 2022-04-18 10:47:10
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3424
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[215] => WP_Post Object
(
[ID] => 3422
[post_author] => 6
[post_date] => 2021-07-01 02:58:21
[post_date_gmt] => 2021-07-01 02:58:21
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-20 06:47:22
[post_modified_gmt] => 2022-06-20 06:47:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3422
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[216] => WP_Post Object
(
[ID] => 3421
[post_author] => 6
[post_date] => 2021-07-01 02:56:30
[post_date_gmt] => 2021-07-01 02:56:30
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2022-04-18 10:51:44
[post_modified_gmt] => 2022-04-18 10:51:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3421
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[217] => WP_Post Object
(
[ID] => 3420
[post_author] => 6
[post_date] => 2021-07-01 02:52:05
[post_date_gmt] => 2021-07-01 02:52:05
[post_content] =>
[post_title] => Fiocruz – AstraZeneca, COVID-19 Technological Order Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => fiocruz-astrazeneca-covid-19-technological-order-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-06 10:03:49
[post_modified_gmt] => 2022-07-06 10:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3420
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[218] => WP_Post Object
(
[ID] => 3418
[post_author] => 5
[post_date] => 2021-06-30 19:06:19
[post_date_gmt] => 2021-06-30 19:06:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:03:49
[post_modified_gmt] => 2022-03-09 13:03:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3418
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[219] => WP_Post Object
(
[ID] => 3417
[post_author] => 5
[post_date] => 2021-06-30 19:04:34
[post_date_gmt] => 2021-06-30 19:04:34
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-11
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:39
[post_modified_gmt] => 2021-09-01 15:12:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3417
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[220] => WP_Post Object
(
[ID] => 3416
[post_author] => 5
[post_date] => 2021-06-30 19:02:19
[post_date_gmt] => 2021-06-30 19:02:19
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:12:57
[post_modified_gmt] => 2021-09-01 15:12:57
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3416
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[221] => WP_Post Object
(
[ID] => 3415
[post_author] => 5
[post_date] => 2021-06-30 19:00:20
[post_date_gmt] => 2021-06-30 19:00:20
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:21:29
[post_modified_gmt] => 2022-09-29 12:21:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3415
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[222] => WP_Post Object
(
[ID] => 3414
[post_author] => 5
[post_date] => 2021-06-30 18:54:43
[post_date_gmt] => 2021-06-30 18:54:43
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 12:29:49
[post_modified_gmt] => 2022-06-27 12:29:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3414
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[223] => WP_Post Object
(
[ID] => 3413
[post_author] => 5
[post_date] => 2021-06-30 18:52:08
[post_date_gmt] => 2021-06-30 18:52:08
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:10:41
[post_modified_gmt] => 2021-09-01 15:10:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3413
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[224] => WP_Post Object
(
[ID] => 3412
[post_author] => 5
[post_date] => 2021-06-30 18:48:13
[post_date_gmt] => 2021-06-30 18:48:13
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:27:17
[post_modified_gmt] => 2022-09-27 09:27:17
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3412
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[225] => WP_Post Object
(
[ID] => 3411
[post_author] => 5
[post_date] => 2021-06-30 18:39:53
[post_date_gmt] => 2021-06-30 18:39:53
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:30:27
[post_modified_gmt] => 2022-07-13 13:30:27
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3411
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[226] => WP_Post Object
(
[ID] => 3410
[post_author] => 5
[post_date] => 2021-06-30 18:37:02
[post_date_gmt] => 2021-06-30 18:37:02
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-01 15:09:38
[post_modified_gmt] => 2021-09-01 15:09:38
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3410
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[227] => WP_Post Object
(
[ID] => 3409
[post_author] => 5
[post_date] => 2021-06-30 18:34:04
[post_date_gmt] => 2021-06-30 18:34:04
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-01-24 12:58:15
[post_modified_gmt] => 2022-01-24 12:58:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3409
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[228] => WP_Post Object
(
[ID] => 3406
[post_author] => 5
[post_date] => 2021-06-30 18:25:58
[post_date_gmt] => 2021-06-30 18:25:58
[post_content] =>
[post_title] => NIH – GeoVax, Non-Exclusive Patent and Biological Materials License Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => nih-geovax-non-exclusive-patent-and-biological-materials-license-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-06-27 12:21:15
[post_modified_gmt] => 2022-06-27 12:21:15
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3406
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[229] => WP_Post Object
(
[ID] => 3372
[post_author] => 5
[post_date] => 2021-06-30 15:06:19
[post_date_gmt] => 2021-06-30 15:06:19
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-12
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:05:39
[post_modified_gmt] => 2022-03-09 13:05:39
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3372
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[230] => WP_Post Object
(
[ID] => 3370
[post_author] => 5
[post_date] => 2021-06-30 15:01:06
[post_date_gmt] => 2021-06-30 15:01:06
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-10
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:09:19
[post_modified_gmt] => 2022-09-29 12:09:19
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3370
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[231] => WP_Post Object
(
[ID] => 3368
[post_author] => 5
[post_date] => 2021-06-30 14:58:39
[post_date_gmt] => 2021-06-30 14:58:39
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-9
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-24 08:10:31
[post_modified_gmt] => 2021-08-24 08:10:31
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3368
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[232] => WP_Post Object
(
[ID] => 3366
[post_author] => 5
[post_date] => 2021-06-30 14:53:53
[post_date_gmt] => 2021-06-30 14:53:53
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 14:53:53
[post_modified_gmt] => 2021-06-30 14:53:53
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3366
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[233] => WP_Post Object
(
[ID] => 3364
[post_author] => 5
[post_date] => 2021-06-30 14:47:34
[post_date_gmt] => 2021-06-30 14:47:34
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-7
[to_ping] =>
[pinged] =>
[post_modified] => 2021-09-02 12:46:22
[post_modified_gmt] => 2021-09-02 12:46:22
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3364
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[234] => WP_Post Object
(
[ID] => 3361
[post_author] => 5
[post_date] => 2021-06-30 14:30:51
[post_date_gmt] => 2021-06-30 14:30:51
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 13:29:04
[post_modified_gmt] => 2022-07-13 13:29:04
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3361
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[235] => WP_Post Object
(
[ID] => 3360
[post_author] => 5
[post_date] => 2021-06-30 14:28:40
[post_date_gmt] => 2021-06-30 14:28:40
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-4
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:25:29
[post_modified_gmt] => 2022-09-27 09:25:29
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3360
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[236] => WP_Post Object
(
[ID] => 3356
[post_author] => 5
[post_date] => 2021-06-30 13:53:23
[post_date_gmt] => 2021-06-30 13:53:23
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-3
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-28 10:44:11
[post_modified_gmt] => 2022-03-28 10:44:11
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3356
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[237] => WP_Post Object
(
[ID] => 3354
[post_author] => 5
[post_date] => 2021-06-30 13:29:21
[post_date_gmt] => 2021-06-30 13:29:21
[post_content] =>
[post_title] => Natick Contracting Division – Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-06-30 13:29:21
[post_modified_gmt] => 2021-06-30 13:29:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3354
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[238] => WP_Post Object
(
[ID] => 3352
[post_author] => 5
[post_date] => 2021-06-30 13:24:49
[post_date_gmt] => 2021-06-30 13:24:49
[post_content] =>
[post_title] => Natick Contracting Division - Ology Bioservices, COVID-19 Procurement Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => natick-contracting-division-ology-bioservices-covid-19-procurement-agreement
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-08 12:52:45
[post_modified_gmt] => 2022-09-08 12:52:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3352
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[239] => WP_Post Object
(
[ID] => 3304
[post_author] => 6
[post_date] => 2021-06-30 09:30:56
[post_date_gmt] => 2021-06-30 09:30:56
[post_content] =>
[post_title] => UK Secretary of State - Roche, REGN-COV2 Supply Agreement
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => uk-government-roche-regn-cov2-supply-agreement-for-pandemic-purposes-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 10:01:21
[post_modified_gmt] => 2021-08-23 10:01:21
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3304
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[240] => WP_Post Object
(
[ID] => 3221
[post_author] => 6
[post_date] => 2021-06-28 12:23:49
[post_date_gmt] => 2021-06-28 12:23:49
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-7
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:47:45
[post_modified_gmt] => 2022-09-27 09:47:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3221
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[241] => WP_Post Object
(
[ID] => 3220
[post_author] => 6
[post_date] => 2021-06-28 12:22:09
[post_date_gmt] => 2021-06-28 12:22:09
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-6
[to_ping] =>
[pinged] =>
[post_modified] => 2022-03-09 13:08:44
[post_modified_gmt] => 2022-03-09 13:08:44
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3220
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[242] => WP_Post Object
(
[ID] => 3219
[post_author] => 6
[post_date] => 2021-06-28 12:19:29
[post_date_gmt] => 2021-06-28 12:19:29
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-5
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-29 12:28:41
[post_modified_gmt] => 2022-09-29 12:28:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3219
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[243] => WP_Post Object
(
[ID] => 3218
[post_author] => 6
[post_date] => 2021-06-28 12:16:20
[post_date_gmt] => 2021-06-28 12:16:20
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-4
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:37
[post_modified_gmt] => 2021-08-23 09:51:37
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3218
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[244] => WP_Post Object
(
[ID] => 3217
[post_author] => 6
[post_date] => 2021-06-28 12:14:37
[post_date_gmt] => 2021-06-28 12:14:37
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-3
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:41
[post_modified_gmt] => 2021-08-23 09:51:41
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3217
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[245] => WP_Post Object
(
[ID] => 3216
[post_author] => 6
[post_date] => 2021-06-28 12:11:22
[post_date_gmt] => 2021-06-28 12:11:22
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet-2
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:51:45
[post_modified_gmt] => 2021-08-23 09:51:45
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3216
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[246] => WP_Post Object
(
[ID] => 3215
[post_author] => 6
[post_date] => 2021-06-28 12:07:55
[post_date_gmt] => 2021-06-28 12:07:55
[post_content] =>
[post_title] => Peru Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-peru-covid-19-vaccine-binding-term-sheet
[to_ping] =>
[pinged] =>
[post_modified] => 2022-07-13 11:33:05
[post_modified_gmt] => 2022-07-13 11:33:05
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3215
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[247] => WP_Post Object
(
[ID] => 3127
[post_author] => 6
[post_date] => 2021-06-03 15:08:41
[post_date_gmt] => 2021-06-03 15:08:41
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-9
[to_ping] =>
[pinged] =>
[post_modified] => 2022-09-27 09:47:06
[post_modified_gmt] => 2022-09-27 09:47:06
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3127
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[248] => WP_Post Object
(
[ID] => 3126
[post_author] => 6
[post_date] => 2021-06-03 15:05:40
[post_date_gmt] => 2021-06-03 15:05:40
[post_content] =>
[post_title] => Dominican Republic Ministry of Health - Pfizer/BioNTech, COVID-19 Vaccine Binding Term Sheet
[post_excerpt] =>
[post_status] => publish
[comment_status] => closed
[ping_status] => closed
[post_password] =>
[post_name] => pfizer-biontech-dominican-republic-binding-term-sheet-8
[to_ping] =>
[pinged] =>
[post_modified] => 2021-08-23 09:52:49
[post_modified_gmt] => 2021-08-23 09:52:49
[post_content_filtered] =>
[post_parent] => 0
[guid] => https://ghiaa.org/?post_type=provision_document&p=3126
[menu_order] => 0
[post_type] => provision_document
[post_mime_type] =>
[comment_count] => 0
[filter] => raw
)
[249] => WP_Post Object
(
[ID] => 3125
[post_author] => 6
[post_date] => 2021-06-03 15:03:17